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ABSTRACT 
Endometrial and ovarian cancers are among the most prevalent malignancies in females all 
around the world. Carcinomas belonging to the type I subset exhibit many similarities in 
their genetic and epigenetic profiles. Lynch syndrome (LS) is one of the most prevalent 
hereditary cancer susceptibility syndromes in the world. LS is a result of defective mismatch 
repair (MMR) caused by a germline mutation in MMR genes, which combined with other 
molecular alterations, is known to accelerate tumorigenesis. In addition to a high 
prevalence in colon cancer, type I endometrial and ovarian cancers predominate in women 
with LS. Apart from the MMR abnormalities, the molecular profile of LS-associated ovarian 
cancer remains unknown. Moreover, the developmental changes occurring in LS patients 
and in the general population prior to endometrial and ovarian cancer are poorly 
understood. Type I endometrial and ovarian non-serous carcinomas are believed to 
originate from the endometrial lining of the uterus, termed the endometrium. Women with 
LS have been offered regular gynecological surveillance in Finland since 1996. This 
surveillance program provides invaluable consecutive endometrial samples before cancer 
diagnosis and represents an excellent model with which to investigate the molecular 
changes resulting in the development of endometrial and ovarian tumors. The aims of this 
thesis were to identify and compare the molecular alterations in LS-associated and sporadic 
ovarian cancer, and to determine genetic, epigenetic and gene expression alterations in 
consecutive specimens prior to the appearance of endometrial and ovarian cancer. 
In total, 213 endometrial and ovarian carcinomas, as well as endometrial biopsy specimens 
from 66 LS mutation carriers were compared to 197 sporadic specimens of the 
corresponding histological types and profiled with established genetic and partly novel 
epigenetic markers. Immunohistochemistry (IHC) was used to analyze the expression of 
MMR, ARID1A, and L1CAM genes, whereas epigenetic DNA methylation alterations of 37 
tumor suppressor genes (TSGs) were evaluated using both commercial and custom-
designed methylation-specific multiplex ligation-dependent probe amplification (MS-
MLPA) assays. Additionally, ovarian carcinomas were investigated by IHC for p53 protein, 
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hypomethylation of LINE-1 marker (a retrotransposon) was detected by MS-MLPA and we 
also conducted a mutational analysis of hotspot sites in KRAS, BRAF, and PIK3CA by PCR, 
followed by sequencing.  
Novel molecular characteristics of LS-associated ovarian cancer were identified: An 
extremely high frequency of loss of ARID1A protein expression, MMR deficiency, no BRAF 
and KRAS mutations, normal p53 protein expression, a unique hypermethylation of 
selected TSGs, and an absence of LINE-1 hypomethylation in endometrioid and clear cell 
ovarian carcinomas, and frequent L1CAM overexpression specifically in clear cell ovarian 
cancer. Molecular analyses of LS surveillance specimens revealed closely related pathways 
in endometrial and ovarian type I tumorigenesis. For example, both MMR deficiency and 
TSG promoter methylation of specific genes appeared in histologically normal endometrial 
tissue preceding endometrial and ovarian cancer and there was ARID1A loss in complex 
hyperplasia with or without atypia prior to the appearance of the endometrial cancer. 
Additionally, we identified a high degree of similarity in the molecular alterations present 
in the hyperplastic lesions that occurred prior to or concurrently with the detection of 
endometrial or ovarian carcinoma collected from the same patient. This discovery suggests 
that endometrial hyperplasia may contribute to the development of ovarian tumors in 
addition to its well-established role in endometrial tumorigenesis. 
Our findings provide novel and valuable information about the gynecological tumorigenesis 
of LS as well as the corresponding tumor with a sporadic origin. Further investigations are 
warranted with larger patient series. Our results may facilitate the prediction of the 
malignant potential of pre-neoplastic specimens, guide treatment decisions and identify 
those women who could benefit from prophylactic surgery. 
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INTRODUCTION 
Cancer is an extensive global cause of death regardless of the endless time and money 
spent on attempts to learn how to control the disease or destroy metastatic cells. Cancer 
is a genetic and epigenetic disease — this means that genetic and epigenetic alterations in 
genes allow cells to function abnormally, especially to grow and divide without control, 
which can ultimately lead to tumor development. Genetics refers to information based on 
the structure of the DNA sequence, whereas epigenetics means the inherited information 
restored in gene expression patterns (1). In fact, genetic and epigenetic events together 
with lifestyle and other environmental influences are closely intertwined in cancer 
development and progression; epigenetic alterations can introduce mutations into genes, 
whereas mutations often occur in genes involved in epigenome modifications (2).  
 
Changes that contribute to tumorigenesis can be inherited from the parents or they can be 
acquired during an individual´s life e.g. from endogenous sources (such as hormones and 
free radicals from cellular metabolism) or external mutagens (such as chemical carcinogens 
from cigarette smoke, physical risk from radiation, and pathogenic bacterial and viral 
infections) as well as errors in DNA replication. In normal cells, these errors are quickly 
repaired by several layers of effective DNA repair mechanisms. Therefore, a damaged DNA 
repair system, such as mismatch repair (MMR) mechanism, may promote tumorigenesis by 
the accumulation of mutations with a growth advantage in the cell´s genome (3).  
 
Lynch syndrome (LS) is a hereditary cancer syndrome, associated with inherited autosomal 
dominant alterations in MMR genes and rare cases in EPCAM gene (4-6). In addition to its 
high prevalence of colorectal carcinomas, as many as 57% and females with LS develop 
endometrial carcinoma and this is also the case in 24% of ovarian carcinomas (7, 8). In 
addition to being common cancers as part of LS, in general, endometrial and ovarian 
carcinomas are some of the most prevalent cancers among women (4th and 8th place, 
respectively), in the United States (9, 10). Survival from ovarian cancer is poor, and 
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regardless of the fact that there are major histological and molecular differences within 
ovarian cancer, the different diseases are currently treated as a single entity. Endometrial 
cancer is the most common but ovarian cancer is the most lethal of gynecological cancers, 
but for both, the molecular changes that precede cancer development are currently 
unknown. Interestingly, epidemiological findings suggest that pathways leading to 
endometrial and ovarian tumorigenesis may intertwine in the early steps of tumor 
development, even before malignant progression. 
 
The unsatisfactory management of most of the ovarian and part of the endometrial 
carcinomas reflects the poor knowledge of what molecular alterations actually lead to 
malignant development, starting from an uncertainty of the cell type of origin. An increased 
understanding of the molecular pathogenesis of ovarian and endometrial carcinoma will 
be required before we can expect improvements in the diagnosis and management of both 
hereditary and sporadic cases. MMR alterations are known to accelerate tumorigenesis in 
LS and sporadic cases (11, 12), but other mechanisms, such as mutations or epigenetic 
hypermethylation of specific genes may be important in the initiation of tumorigenesis but 
also in determining in which tissue and how fast tumor development progresses.  
 
LS offers an excellent model with which to study epigenetic factors that facilitate 
tumorigenesis, since both the genotype and phenotype of a patient with LS often display a 
poor correlation. In addition, LS is an invaluable model for investigating the molecular 
changes preceding endometrial and ovarian cancer, as the basic tumorigenesis in LS 
significantly resembles that in corresponding sporadic cases but is accelerated. 
Furthermore, invaluable consecutive endometrial biopsy specimens from surveillance 
against gynecological cancer are available from these patients (13). Since the risk for 
gynecological carcinomas among LS mutation carriers increases after 40 years of age (7, 
14), prophylactic surgery is recommended around that age, but its exact optimal timing 
remains an open question. Molecular findings from biopsy specimens could help to resolve 
this question. 
Introduction 
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REVIEW OF THE LITERATURE 
1 Cancer – Overview 
Cancer is a diverse disease of multiple organs as a result of genetic and epigenetic 
alterations in specific genes, which disrupt the cells’ abilities to maintain normal growth 
and division. Although the start of cancer development is monoclonal, the high rate of new 
mutations and the different forms of genomic instability soon divide cancer cells into new 
populations (15). In 2000, Hanahan and Weinberg (16) proposed six hallmarks that all 
cancers have in common and which explain the properties that permit cancer cells to live, 
divide and spread. Every cancer is a unique combination of these hallmarks and aberrations 
that may occur in changing orders or simultaneously. The hallmarks include (1) the ability 
of cancer cells to stimulate their own proliferation, (2) the cancer cells are resistant to 
signals that inhibit their growth, (3) they have the capacity to avoid cell death, (4) they have 
an endless potential to replicate, (5) they possess a capability to grow and maintain blood 
vessels, and (6) cancer cells display a potential to move from the original site to invade 
distal organs (16). In 2011, the same scientists added two emerging hallmarks, the ability 
of cancer cells to modify cellular metabolism and to escape from immune destruction, as 
well as two facilitating hallmarks known as genome instability and inflammation which 
facilitate cancer cells to receive the main core and emerging hallmarks (17). In addition to 
these well-known hallmarks, another important hallmark exists; global alterations in the 
epigenetic landscape (18). Moreover, epigenetic mechanisms may be involved in each of 
the hallmarks proposed.  
 
In the United States, it is predicted that around 1 735 350 new cancer cases will be 
diagnosed in 2018 (19). The most prevalent cancers in the Finnish population are shown in 
Table 1. On the positive side, the cancer death rate is declining (especially the death rates 
of the most common cancers of lung, colorectal, breast, and prostate), due to a reduction 
in smoking, early diagnosis and improvements in treatment.  
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Table 1. The five most common cancers in Finland and cancers included in the study (in 2015). 
 
*relative to world standard population by age adjusted, 1/100 000 people (20). 
 
2 Tumorigenic pathways 
Genetic and epigenetic alterations that contribute to cancer mainly affect two major types 
of genes: Tumor suppressor genes (TSGs) and proto-oncogenes, which are involved in the 
growth and division of normal cells. DNA repair genes are an important subclass of TSGs, 
tightly implicated in normal cellular functions (21). In cancer, proto-oncogenes become 
activated to become oncogenes that drive cell division or prevent cells from apoptosis 
(programmed cell death) whereas TSGs become silenced so that they cannot resist these 
oncogenic processes to happen (22). Moreover, DNA repair genes become faulty and lead 
to permanent DNA damage, thus causing the accumulation of mutations. Although 
thousands of alterations in different genes take place in a neoplastic cell, only 
approximately 140 of those are so-called driver genes which have the ability to promote 
tumorigenesis. Usually, 2 to 8 driver gene mutations are found in a tumor and all the rest 
(more than 99.9% of the alterations) are passenger mutations which do not enhance nor 
impair the tumor growth (21). The driver genes are involved in key processes of a cell, 
including specific cell fate, cell survival, and genome maintenance (21).  
 
 
 
Primary 
cancer
Order of prevalance New cases Deaths Incidence*
Breast 1. 5161 841 96.9
Colon 2. 1014 394 14.13
Skin, non-melanoma 3. 789 30 7.9
Lung and trachea 4. 936 779 13.27
Endometrium 5. 846 203 12.55
Ovarian 10. 436 349 7.12
Prostate 1. 4855 921 78.77
Lung and trachea 2. 1690 1456 27.36
Bladder and urinary tract 3. 991 217 15.42
Colon 4. 981 378 16.09
Skin, non-melanoma 5. 896 32 12.68
Female
Male
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2.1 Altered tumor suppressor genes and proto-oncogenes in cancer 
Mutations affecting proto-oncogenes are typically dominant and speed up tumorigenesis 
by a gain of function in gene expression, leading to enhanced cell division or prevention of 
cell death. KRAS is the most commonly altered proto-oncogene in cancer (23); it encodes a 
GTPase, a key component of the P13K/AKT pathway, and this proto-oncogene plays an 
important but stringently regulated role in normal cell signaling growth. However, 
mutations in KRAS can transform it into a constitutively active oncogene, causing over-
production of its gene product further promoting uncontrolled growth (24, 25).  
 
In contrast to proto-oncogenes, mutations and epigenetic alterations that occur in TSGs 
are frequently recessive, meaning that both of their parental alleles need to be inactivated 
(by Knudson´s “two- or multiple hit” hypothesis) to achieve complete expression of the 
modified phenotype (26, 27).  TSGs can be silenced by different kinds of “hits”, such as 
mutational inactivation, loss of heterozygosity (partial or complete loss of gene) or the gene 
can be turned off by epigenetic mechanisms (2). Occasionally, inactivation of only one allele 
of a TSG may predispose to a change in gene expression; in haplo-insufficiency, one allele 
alone is unable to produce a wild-type phenotype (28). This can also be achieved by a 
situation in which one mutated allele can disturb the function of the other allele by 
dominant-negative manner. p53 is a good example of a crucial TSG often associated with 
different cancers; it is also known as “the guardian of the genome”, which in normal cell 
becomes active in response to DNA damage (29, 30). Loss of expression of p53 increases 
cell proliferation (31) and interrupts p53-dependent cell death promoting tumorigenesis 
(32).  
 
2.1.1 An epigenetic tumor suppressor, ARID1A   
A recent intriguing finding in cancer research, discovered through whole genome 
sequencing, has been the realization that nearly all cancers harbor alterations in genes 
involved in creating the epigenetic machinery. These modified genes may therefore alter 
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the epigenome, resulting in changed gene expression and evoking genomic instability. 
Moreover, the frequency of many of these mutations is sufficiently high to suggest that 
they are “driver” mutations, meaning that a disturbance of the epigenome may be an early 
event in the initiation of cancer (2, 33).  ARID1A, a gene involved in chromatin/nucleosome 
remodeling, is one of these genes often altered in several different types of cancer (34). 
 
ARID1A (AT-rich interaction domain 1A) is a TSG which is often mutated in human cancers 
and believed to play a role both in tumor initiation and progression (35). ARID1A encodes 
a large protein, BAF250a, a key component of the ATP-dependent chromatin remodeling 
complex SWI/SNF (switch/sucrose non-fermentable). This complex regulates the 
transcription of specific genes by changing the accessibility of the chromatin around gene 
promoters; it is involved in several cellular processes such as DNA synthesis, DNA repair 
and genomic stability (36). As part of the chromatin remodeling complex, ARID1A is able to 
inhibit cell growth in normal cells (37). Disrupted ARID1A may cause distinct problems in 
SWI/SNF complexes, including a disturbance of nucleosome sliding, targeting to certain 
genomic sites and the assembly of coactivators or corepressors (38). Mutations in ARID1A 
are expected to lead to direct epigenetic modifications in cancer cells by changing the 
chromatin structure. Therefore, mutated ARID1A in cancer can partly explain why DNA 
methylation and chromatin differ between cancer and normal cells (39).  
 
2.2 DNA repair 
Despite the massive amount of errors that occur in a cell’s genome, only a very low number 
(10-7-10-11bp/cell generation) of mutations remain in the genome due to the multilevel 
repair mechanisms that proofread DNA and correct most of the genomic alterations (40). 
Most mutations that are left in the genome are harmless to the cell, but on rare occasions 
the cell acquires a growth promoting mutation that will confer on the cell ability to achieve 
the hallmarks of cancer and eventually become neoplastic (16, 17, 41). If a defence 
mechanism such as MMR becomes defective, mutations start to build up high rate in a 
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cell´s genome, causing hypermutability and an increased risk for additional destructive 
mutations that often lead to tumor development. 
There are a variety of DNA repair strategies, each repairing specific types of damage and 
restoring lost information. For instance, base excision (42), nucleotide excision (43) and 
mismatch repair (44) are needed to repair single-strand breaks on DNA, whereas double-
strand breaks are often repaired by non-homologous end joining or by homologous 
recombination (45). 
 
2.2.1 DNA mismatch repair (MMR) 
The mismatch repair (MMR) machinery plays a critical role in the protection of genome 
stability by recognizing and stimulating repair of base pair mismatches and 
insertion/deletion loops in DNA caused by environmental factors and cellular processes as 
well as replication errors that escape DNA proofreading (46). Figure 1 illustrates the MMR 
repair of single base pair mismatches. Defects in MMR cause an accumulation of small 
mono- and dinucleotide deletions and insertions, which lead to a variable number of these 
repeats causing microsatellite instability (MSI) (see Chapter 2.3.2 below). MSI can be used 
as a marker to detect MMR deficiencies (47). Defective MMR promotes tumorigenesis in 
two alternative ways: First, defective MMR causes increase in the number of replication 
errors leading to hypermutability, which may increase tumor heterogeneity and generate 
mutations, which are advantageous for neoplastic cells (3). Second, the absence of sensors 
for DNA damage, may lead to accelerated cell divisions and evading apoptosis (48). 
 
Both genetic and epigenetic silencing of many genes have been implicated in the MMR 
pathway (4). A defective MMR system may be the starting point for tumorigenesis and 
inherited aberrations in the MMR machinery are well known to underlie a hereditary 
cancer syndrome called Lynch syndrome.  
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Figure 1. Simplified outline of the MMR pathway. Three main steps are involved in MMR repair: (1) 
Recognition of damaged DNA and initiation of repair, (2) excision of mismatched DNA and (3) 
resynthesis. (1) The DNA damage is recognized by the hMutSα complex, consisting of a MSH2 and 
MSH6 heterodimer, which binds to single base pair mismatches (as shown in the figure). The MSH2 
and MSH3 heterodimer, called hMutSβ complex, detects longer insertions or deletions (not shown). 
Proliferating cell nuclear antigen (PCNA) is also involved in the recognition of mismatches. (2) After 
the recognition of DNA damage, the hMutLα complex, consisting of MLH1-PMS2 heterodimer, is 
recruited to the site and starts dissembling the mismatched DNA by exonuclease EXO1. (3) Finally, a 
new complementary strand of DNA is synthesized by DNA polymerase δ and further ligated to the 
old, undamaged strand by DNA ligase I. 
 
2.3 Genomic Instability  
Genomic instability in cancer is the driving force that leads to genetic heterogeneity inside 
a tumor, generating the genetic diversity for cancer cells to survive through natural 
selection, and providing extensive variety in patient phenotypes (49, 50). Genomic 
instability is a feature of nearly all human cancers, but the molecular basis and the time 
point when it arises in carcinogenesis remains still largely unknown. In hereditary cancer, 
this phenomenon has been linked to defective DNA repair mechanisms causing a high 
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spontaneous mutation rate (mutator hypothesis) (51) which is present already in 
precancerous lesions and confers on the neoplastic cell an ability to undergo favorable 
genetic changes and to achieve the hallmarks of cancer (17, 52). On the other hand, the 
molecular background of genomic instability in sporadic cancer is still not fully understood. 
It has been proposed that oncogene-induced errors in DNA replication as well as telomere 
erosion could be at least partly responsible for the genomic instability encountered in 
sporadic tumors (53, 54). Chromosomal instability (CIN) and MSI are two distinct forms of 
genomic instability (55, 56).  
 
2.3.1 Chromosomal instability (CIN) 
The amount of chromosomal alterations is highly increased in cancer, and it is the major 
form of genomic instability in cancer occurring in more than 90% of solid tumors (57). 
Alterations that contribute to CIN are large-scale rearrangements of the chromosome 
structure and number, involving aneuploidy (changes in numbers of chromosomes) as well 
as intrachromosomal inversions, deletions, translocations and amplifications (55, 58). 
Aneuploidy is a consequence of unequal division of chromosomes to daughter cells in 
mitosis and this feature of CIN is unique to neoplastic cells as the accurate arrangement 
and the number of chromosomes is strictly regulated in normal cells (55). CIN provides 
cancer cells with the possibility to obtain heterogeneity, allows them to rapidly collect 
mutations and modify tumor genomes, which further drives tumor progression (59).  
 
2.3.2 Microsatellite instability (MSI) 
Microsatellite DNA refers to short repeated sequences of DNA (typically dinucleotides) 
scattered throughout the human genome. The lengths of the repeats vary among the 
population, but are unique in an individual (60, 61). A defective MMR system can lead to 
an accumulation of base pair mismatches in microsatellites causing MSI; this can be 
observed as deletions or insertions of only a few nucleotides at repeat sequences (47, 62). 
MSI is a characteristic of almost all LS-associated tumors (over 90% of colorectal and 
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endometrial carcinomas (63, 64) but additionally, acquired aberrations in the MMR system 
are estimated of being the causal factor in 15 to 20% of colon and up to 30% of endometrial 
cancers of sporadic origin (63, 65-67). These sporadic carcinomas develop as a result of a 
defective MMR machinery caused by a somatic mutation or by DNA methylation (68). 
Tumors displaying MSI show a major acceleration of the mutations rate by between 100 to 
1000 fold in comparison with normal cells (69).  
 
3 Epigenetics and Cancer 
The initiation and progression of cancer by silencing of TSGs, activation of oncogenes and 
the acquisition of genomic instability is achieved by genetic and epigenetic dysregulation.  
Epigenetics refers to all of the mechanisms involved in the regulation of gene expression 
not involving changes in the primary DNA sequence (70). Thus, in contrast to genetic 
mutations, epigenetic alterations (epimutations) do not alter the genetic code of the DNA 
itself but are able to regulate gene expression by other, potentially reversible, mechanisms. 
Furthermore, epigenetic regulation is affected by genetic factors and the environment. 
Epigenetic mechanisms consist of DNA methylation, histone modifications, non-coding 
RNAs (mainly miRNA expression) and modifications of chromatin remodeling systems 
(demonstrated in Figure 2). These epigenetic mechanisms which carefully regulate normal 
homeostasis of expressed genes in a cell, become completely disrupted in the neoplastic 
cell (1). Additionally, recent findings from next-generation sequencing (NGS) of whole 
cancer genomes have shown that epigenetic genes, for instance those encoding parts for 
chromatin remodeling machinery as well as enzymes that modify histones, are frequently 
mutated in cancer, transforming them to behave like TSGs or oncogenes (71, 72). 
 
The reversible but heritable nature of epigenetic aberrations has led to the emergence of 
the promising field of epigenetic therapy, which is already making progress with the recent 
FDA approval of four epigenetic drugs for use in the cancer treatment of T-cell lymphomas 
and myeloma (73). 
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Figure 2. Epigenetic alterations in cancer, including DNA methylation (A), histone modifications (B), 
miRNAs (C) and chromatin modifiers (D). A (top), in cancer, TSG promoters become methylated 
(black balls) and silenced (bent arrow indicates the transcription starting point); A (bottom), 
oncogene promoters become hypomethylated and activated (open arrow indicates low and solid 
arrow high expression). B, The number of inactivating histone marks increases in cancer cells 
resulting in compact chromatin and silencing of TSGs. C (top), inactivation of a TSG by increased 
oncogenic miRNA expression; C (bottom), oncogene activation by decreased expression of tumor 
suppressive miRNA. D, chromatin remodeling complex SWI/SNF modifies chromatin accessibility. In 
normal cells (left), SWI/SNF-complex activates genes normally silenced by packed chromatin 
structure established by HDACs. SWI/SNF complex represses expression of HDACs leading to active 
chromatin and expression of genes regulated by HDACs. In cancer (right), the loss of ARID1A, 
expression leads to a dysfunction in the SWI/SNF-complex resulting in expression of HDACs, 
subsequent repressive chromatin state and inactivation of genes targeted by HDACs. Modified from 
Peltomäki et al. (74) 
Review of the Literature  
  
20 
 
3.1 DNA hypermethylation and cancer 
DNA methylation is an epigenetic change in DNA sequence that typically occurs at a 
5´cytosine located next to guanine forming CpG dinucleotides (2). Patterns of DNA 
methylation are established in the early stages of development and maintained 
respectively stable throughout life. Furthermore, methylation patterns are frequently 
inherited to daughter cells in cell division (75) and even aberrant hypermethylation 
(epimutations) of specific TSGs has been shown to be inherited in the germline from 
parents to progeny (76, 77). Particularly stable form of DNA methylation is involved in 
genomic imprinting which is a way of silencing gene expression of one parental allele by 
DNA methylation (78). DNA methylation in humans is produced and maintained by DNA 
methyltransferase (DNMT) enzymes, which add a methyl group (CH3) into the 5´ position 
of a cytosine adjacent to a guanine (by DNMT1) and maintain (by DNMT3A and DNMT3B) 
the methylation through cell divisions. On the contrary, 10–11-translocation proteins (TET) 
can remove methyl groups and further demethylate DNA (79).  
 
In human genome, approximately 60% of gene promoters contain a high number of CpG 
dinucleotides, called CpG islands (80). The DNA methylation patterns of these islands are 
tissue specific (81). Hypermethylation of CpG islands around gene promoters is associated 
with inactivation of the gene. In normal cells, most of the CpG islands around gene 
promoters are unmethylated, as it allows open and active chromatin and expression of 
genes when equivalent transcription factors are accessible. In contrast to 
hypermethylation and consequent inactivation associated with promoters, 
hypermethylation that occurs in a gene body either enhances or has no effect on gene 
expression (2). In cancer, usually 5 to 10% of CpG sites located in gene promoters become 
heritably hypermethylated (33). This may cause transcriptional inactivation of the TSGs, 
which in normal conditions would suppress tumor formation (18, 33, 82). These alterations 
in methylation are believed to drive the cancer formation as they appear already in early 
stages of cancer development (83). Genes known to be hypermethylated in cancer are 
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involved in all of the key cellular pathways, such as the cell cycle (CDKN2B), DNA repair 
(MLH1), metabolic reprogramming (VHL) and cell death (DAPK) (1, 79).  
 
Abnormal hypermethylation of gene promoters is a main mechanism associated with 
tumor suppressor gene inactivation in carcinogenesis (See Figure 2A) (84). In nearly all 
cancer types, hundreds of genes may be silenced by promoter hypermethylation. However, 
only a small fraction of these hypermethylated genes are “drivers” and hence affect cancer 
initiation and progression (2, 85). Three main routes involving DNA methylation are known 
to promote tumorigenesis. These changes often occur concurrently and include genome-
wide hypomethylation, specific hypermethylation of TSG promoters, and direct mutational 
processing of sites containing methylated cytosines by ultraviolet radiation, deamination 
or by other carcinogenic mutagens (2, 86). 
 
DNA methylation has been utilized as a biomarker in diagnosis, prognosis, and in response 
to treatment (79). At the present, clinical treatments with demethylating agents have been 
limited by their non-specific nature. This may change in the future, as the CRISPR-mediated 
system holds the promise of site-specific epigenetic editing of the genome (87).   
 
3.2 Hypomethylation, LINE-1 and cancer  
Hypomethylation, the genome-wide decrease in 5-methylcytosine, was the first epigenetic 
alterations identified in human tumors (88). Global hypomethylation is often a 
characteristic of tumor progression but sometimes it can be also observed in the early 
stages of tumor development (89, 90). Hypomethylation is a frequent feature of cancer 
cells and in contrast to hypermethylation of CpG sites in gene promoters, hypomethylation 
is often present in the remainder of the genome and can be detected in vast areas of the 
genome. Hypomethylation stimulates carcinogenesis in diverse ways such as activating 
oncogenes (91), generating CIN by disruption of genes via retrotransposition of long 
interspersed element 1 (LINE-1), and by loss of imprinting (LOI) (92, 93). LOI activates an 
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allele that has been imprinted and therefore silenced by DNA methylation and this 
activation will result in an overabundance of the gene product expressed now by both 
alleles (94). 
 
Highly repeated DNA sequences, such as the interspersed Alu and LINEs comprise nearly 
half of the human genome, and are the typical place for hypomethylation to take place. 
LINE-1 retrotransposon, up to 6 kb in length and the only active and abundant LINE-element 
still in human, provides a useful marker to measure global hypomethylation of the cancer 
cell genome (95, 96). DNA hypomethylation activates LINE-1 transcription and enables the 
retrotransposition of these elements into new sites in the genome. In tumor development, 
these elements can disrupt gene function by insertion and can also act as surrogate splice 
sites or as alternative promoters (93). Alterations in DNMTs and TET2 have been detected 
in some cancers which may cause global hypomethylation (79).  
 
3.3 Histone modifications  
DNA in the human nucleus is tightly wrapped around histone proteins. Histones have an 
unfolded domain, called the histone tail, which is bound by different epigenetic marks (see 
Figure 2B). These epigenetic signatures on histone tails contribute to packing of the 
chromatin and influence the binding of proteins to chromatin. The histone tails can be 
modified with many different chemical bounds, such as methylation, acetylation, 
phosphorylation and ubiquitination (97, 98). The chemical modification together with its 
position of the histone tail, specify influence the chromatin. For example, trimethylation of 
lysine 4 in histone 3 (H3K4Me3) is an activating signal, whereas the same modification in 
lysine 9 in histone 3 (H3K9Me3) mediates a repressive function. Furthermore, the 
modification with a different chemical of the same position may produce an opposite event 
such as acetylation of lysine 9 in histone 3 (H3K9ac) may cause an activation of transcription 
(79). In cancer, these covalent histone marks around promoter regions often become 
altered together with DNA methylation changes (2, 82, 99).  
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3.4 MicroRNAs 
MicroRNAs (miRNAs) are another set of crucial factors involved in epigenetic regulation. 
MiRNAs belong to small non-coding RNAs, which regulate the expression of selected genes 
at the post-transcriptional level (100). MiRNAs regulate the translational processing of 
genes by specific targeting of 3´-untranslated region of messenger RNA (mRNA) followed 
either by target mRNA degradation or by blocking mRNA translation into protein. MiRNAs 
may be important players in tumor development, because they target and consequently 
regulate specific proto-oncogenes (tumor suppressive miRNAs such as miRNA let-7a which 
inhibits MYC oncogene) (101) and TSGs (oncogenic miRNAs such as MIR34B) as shown in 
Figure 2C, and furthermore, miRNAs may mediate regulatory communication between 
oncogenes and TSGs in carcinogenesis (102). In addition, MiRNAs directly target 
components of the epigenetic machinery, such as DNMTs (103) and histone deacetylases 
(HDACs) (104), resulting in indirect modulation of genes regulated by epigenetic 
modifications (105). 
 
On the contrary and making this network even more complex, miRNA themselves can be 
regulated at the transcriptional level by binding of specific proto-oncogenes and TSGs to 
miRNA host gene promoter which encode miRNA (106), as well as through genetic 
alterations of the host gene promoter (107). Moreover, recent breakthrough findings have 
shown that the genes encoding for miRNAs can also be epigenetically regulated by 
promoter methylation, acetylation and methylation of histones as well as chromatin 
modifications (105, 108). This ability of a cancer cell to epigenetically regulate specific 
miRNAS may help the cell to transform its transcriptome to an oncogenic phenotype.  
 
3.5 Chromatin modifiers in cancer 
Defective epigenetic machinery may often underlie the epigenetic alterations in a cancer 
cell´s genome as demonstrated in Figure 2D (2). During cancer progression, the 
maintenance of transcriptionally repressed and active chromatin states becomes altered. 
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Therefore, chromatin modifiers and their alterations may play a major part in 
carcinogenesis. Several candidates have been acknowledged: HDACs are proteins that 
remove acetylation from histones as well as from other proteins and establish a tightly 
packed and silenced chromatin structure (109). Other candidates are histone 
acetyltransferases (HATs), which function as transcriptional activators by adding acetyl-
groups to histone tails, as well as the SWI/SNF protein complex, together with its subunit 
ARID1A, which actively modifies the chromatin around promoter regions as well as 
changing the localization of nucleosomes to promote gene expression (1, 38). 
 
3.6 Technology to identify DNA methylation changes 
There are many different techniques available for analyzing gene-specific or genome-wide 
DNA methylation patterns. The determination of the DNA methylation patterns and their 
distribution in the genome is essential in understanding their function in normal cellular 
functions as well as in disease, such as cancer. These techniques are primarily divided into 
three categories depending on the pre-treatment step applied: (1) Restriction enzyme 
based assays, (2) affinity enrichment based assays, and (3) sodium bisulfite based assays 
(110, 111). The optimal choice for DNA methylation assay depends on several aspects such 
as the scientific question, the amount and quality of the sample to be analyzed, the 
information available of the sequence under analysis, the required sensitivity of the assay, 
the bioinformatics knowledge available, as well as economic issues.  
 
For many methods, the limiting factor is the high quality and/or large quantities of DNA 
required and therefore only a few assays are suitable for formalin-fixed paraffin embedded 
(FFPE) samples. Many assays, such as restriction landmark genomic scanning (RLGS) and 
the methylated-CpG island recovery assay (MIRA) require high quality DNA, but for 
instance, Illumina Infinium 450K assay can be used to analyze low quality, FFPE samples 
(110, 112, 113). As the whole-genome methylation assays have developed becoming more 
sensitive and cheaper, they are replacing the methods used to analyze gene-specific 
methylation. Still today, gene-specific methods are pivotal due to their low cost, their 
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ability to generate quantitative data, the possibility to detect methylation changes from 
low quality FFPE DNA (such as MS-MLPA), and in cases where the interest in detecting DNA 
methylation only requires a low number of specific genes, such as MLH1 methylation in 
colorectal and endometrial cancer (5). In addition, the plethora of data produced by whole-
genome methylation assays, require time and bioinformatics knowledge to sort out the 
data, whereas analyzing gene-specific methylation is often fast and requires less 
bioinformatics skills.   
   
New platforms using NGS and/or genome-wide hybridization to investigate genome-wide 
DNA methylation patterns have enabled the identification of large sets of genes 
methylated in cancer (67, 114). The widely used, Illumina Infinium 450K microarray 
platform detects around 450,000 candidate CpG sites throughout the genome giving a 
broad perspective of the methylation changes in the human genome. Although, the 
coverage of this platform is broad, it is not very specific in a given region of the genome 
and thus it is mainly used as a first screening method and subsequently followed by 
methods that carry a higher number of probes for a specific region (115). In addition, direct 
sequencing of all CpG sites after bisulfite modification of DNA (for instance, whole genome 
bisulfite sequencing, WGBS) (116) is currently available and allows extensive information 
of nearly all CpGs throughout the genome (117).  
 
4 Hereditary cancer 
Most cancers are caused by somatic mutations in driver genes, but around 10% of cases 
are a consequence of a germline mutation that may be inherited from parents to offspring. 
More than 110 genes are known to be associated with hereditary cancer syndromes (118). 
The most common inherited alterations involved in hereditary cancer are due to defects in 
DNA repair genes (119).  
 
Most hereditary cancer syndromes are passed on to the children in an autosomal dominant 
manner and in most cases, a carrier is heterozygous for the inherited germline mutation. 
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This means that the carrier inherits one defective allele of a specific TSG (the so-called first 
hit in Knudson´s two hit hypothesis) (26, 27) which increases the risk for developing cancer, 
but only after the second somatic hit has been acquired in a cell of a target tissue, may 
tumor development be initiated. In sporadic cancer however, two hits affecting both alleles 
of a TSG need to occur somatically before tumor development can begin. Either one or 
both of these inactivating hits can occur genetically or epigenetically. Examples of 
hereditary autosomal dominant cancer syndromes include Lynch syndrome (described 
below), hereditary breast and ovarian cancer syndrome (described below), and Peutz-
Jeghers syndrome (germline mutation in STK11 gene) (120) which predispose to several 
cancers, whereas familial adenomatous polyposis (germline mutation in APC gene) mainly 
predisposes to colon cancer (121). 
 
4.1 Lynch syndrome  
Lynch syndrome (LS, OMIM #120435, #120436), earlier referred to as hereditary non-
polyposis colorectal cancer syndrome (HNPCC), was first reported by Doctor Aldred Scott 
Warthin in 1913 (122). Patients with LS were defined according to clinical and family history 
alone until the year 1993, when Peltomäki et al. (123) identified the first susceptibility locus 
for this syndrome. LS is a severe hereditary cancer susceptibility syndrome caused by 
autosomal dominant mutation or epimutation in one of the genes belonging to the MMR 
system (5). LS mutation carriers have a high risk of developing early onset colon or 
gynecological cancer (endometrial and ovarian) and most tumors present with a MSI 
phenotype due to aberrant MMR (124). Most women with LS become affected with 
endometrial and/or ovarian cancer at some stage of life and the latest analysis of cancer 
risk in LS patients has shown that the risk of gynecological cancer in women with LS 
outweighs the risk for colon cancer (7). Other cancer types such as stomach, urinary tract, 
bladder, breast, brain (glioblastoma) and cancer of the kidney are less common in LS 
patients but nonetheless, the incidence exceeds that of average population (see Figure 3) 
(125, 126). MMR genes are expressed in all tissues, but the cancer risk varies according to 
Review of the Literature  
  
27 
 
the tissue. This may be a consequence of the amount of MMR product produced in the 
tissue, the proliferation rate of cells, the power of immune defense, and the way in which 
the tissue has been exposed to endogenous or exogenous carcinogenic agents (127). It is 
typical that an LS mutation carrier may be diagnosed with different cancers in their life but 
fortunately, the survival is higher for most cancers compared to sporadic cancers (8). The 
incidence of an individual with Lynch syndrome developing any type of cancer before the 
age of 70 is 75% in women and 58% in men (8).  
 
Figure 3. Cumulative cancer risk of LS-associated cancers from age 25 up to 75 years of age in general 
population and in LS germline mutation carriers. Cumulative risk values in general population are 
shown for females only (pink color). The cancer risk in Lynch syndrome for endometrial, ovarian, 
and breast cancer is shown in females only; for all other cancers, the risk values are shown for 
combined genders. In LS-associated cancers, the cumulative risk is shown separately in MLH1, MSH2 
and MSH6 mutation carriers, respectively (green color). The data for general population is collected 
from the NORDCAN-database (128, 129) and for Lynch syndrome from Møller et al. (2017) (130). 
Review of the Literature  
  
28 
 
The incidence of LS in the population can be as high as 1 in every 370 individuals and even 
this value may be an underestimation (124). It has been estimated that there are more than 
10 000 LS mutation carriers in Finland and over a million in Europe, moreover, LS has been 
evaluated as being the causal factor in 3% of the newly diagnosed colorectal carcinomas 
(5). In Finland, there are currently approximately 280 known families with a verified 
mutation causing LS (131). Because of the dominant characteristic of the LS causing 
mutation, the risk for passing on a defective allele to a child is 50%. In a rare condition, 
constitutional MMR deficiency (CMMRD), the child inherits defective MMR alleles from 
both parents causing a severe form of cancer syndrome and in which cancers (mainly 
hematological malignancies, colorectal cancer, and brain tumors) occur already in 
childhood (132).    
 
LS is a consequence of germline mutation in one of the MMR genes (MLH1, MSH2, MSH6 
and PMS2), or by a large deletion in EPCAM gene. EPCAM germline mutation is a rare event, 
but it can also cause LS by epigenetic inactivation of its adjacent MSH2 promoter by DNA 
hypermethylation followed by silencing of MSH2 gene (6, 133). Almost 3500 unique LS-
associated variants have been discovered in MLH1, MSH2, MSH6, PMS2 and EPCAM, and 
the shares of the variants among MMR genes are approximately 38%, 33%, 19%, and 10% 
respectively (134). On rare occasions, Lynch syndrome may be inherited via a constitutional 
epimutation (135). This means that hypermethylation of a specific allele (non-imprinted), 
such as MLH1 in LS, occurs in a germline and is therefore spread throughout the normal 
tissues in the body. This constitutive epimutation of MLH1 is typically the first hit and LOI 
frequently the second hit that inactivates the gene and drives tumor formation in a tissue 
(76). Clinically, this resembles the MLH1 mutation or methylation of MLH1 in sporadic cases 
(136). On the contrary, an MSH2 epimutation is secondary and caused by a deletion of the 
EPCAM gene (6, 77). In LS-associated cancers both two hits, hereditary and later acquired 
somatic, are frequently genetic (MMR or EPCAM) (137, 138).  
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4.1.1 Diagnostics and screening pathways  
The identification of colorectal and gynecological carcinoma patients with LS is important 
in order to save lives by guiding these patients and their affected relatives to surveillance 
programs and to start prevention interventions. It has been estimated that colonoscopy 
surveillance for colorectal carcinoma in verified LS patients decreases the overall death 
incidence from colorectal carcinoma by 65% (139). The estimates with gynecological 
surveillance have not shown a similar effect (140). However, Auranen and Joutsiniemi 
(2011) performed a systematic review of gynecological surveillance in women with LS and   
revealed a 5% to 6.5% detection rate of pathological endometrial findings in surveillance 
visits that involved endometrial biopsies (141). 
 
Different guidelines (Amsterdam Criteria and Bethesda Guidelines) have been developed 
for clinicians to identify colorectal and endometrial carcinoma patients that have a high risk 
of being LS mutation carriers and who should be guided to further analysis of MMR defects 
(142-145). The problem with these guidelines is that they are either not sensitive 
(Amsterdam Criteria) or specific (Bethesda Guidelines) enough and hence most Lynch 
mutation carriers remain undetected. The currently used guidelines Amsterdam criteria II 
(145) and Bethesda (revised in 1999) (143) for LS diagnosis are shown in Table 2. 
Table 2. Amsterdam Criteria II and revised Bethesda guidelines for diagnosis of LS. 
 
aLS-spectrum tumors include CRC, endometrial, ovarian, stomach, urinary tract, bladder, breast, 
brain (glioblastoma), skin, pancreas, and cancer of the small bowel. bMSI-high histology is 
determined as the presence of tumor-infiltrating lymphocytes, mucinous/signet-ring differentiation 
or medullary pattern of growth. Abbreviations: LS, Lynch syndrome; CRC, colorectal cancer. 
Amsterdam Criteria II
2. Affected individuals detected in two generations
3. At least one of the LS-associated cancersa, diagnosed under 50 years of age
4. Familial adenomtous polyposis (FAP) excluded in CRC cases
Revised Bethesda guidelines
1. CRC diagnosed in an individual under 50 years of age
2. Synchronous or metachorous LS-associated tumorsa detected regardless of age
3. CRC tumor with MSI-high histologyb diagnosed in an individual under 60 years of age
5. Diagnosis of CRC in at least two first- or second-degree relatives with LS-associated tumors, at any age.
4. Diagnosis of CRC in at least one first-degree relative with LS-associated tumor, with one of the tumors
 diagnosed under 50 years of age
1. At least three relatives with LS-associated cancera, of whom one affected individual is a first-degree 
relative of the other two. 
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If patient is suspected of being LS, at present immunohistochemical (IHC) analysis of MMR 
genes is recommended. This analysis is able to detect an absent MMR protein and thus 
identifies which MMR gene to test by mutational analysis in order to find out the exact 
mutation causing the syndrome (146). If the absence of MLH1 is detected by IHC, an 
additional methylation analysis of MLH1 promoter is needed before mutational testing to 
exclude common sporadic cases caused by methylation of MLH1 gene promoter (5).  
 
The final identification of LS mutation carriers is based on the detection of MMR or EPCAM 
germline mutations which can be found by sequencing. At present, a tumor sample is 
needed in the characterization of a mutation, but a functional assay is being developed that 
would detect a MMR deficiency from a healthy relative by using fibroblasts (147). Until the 
present time, sequencing has been expensive and time-consuming and the analysis and 
interpretation of sequencing data of MMR genes have required substantial effort due to 
their large size and high number of variants known in these genes. Therefore, only patients 
showing convincing proof by fulfilling clinical criteria of LS and having a defective MMR by 
IHC are at present guided to undertake final genetic testing. All verified mutation carriers 
should be provided with genetic counseling and enrolled into surveillance programs to 
prevent cancer development (5). Families meeting the clinical criteria of LS but showing 
negative for tested predisposing mutations should be considered for further epigenetic 
testing to exclude constitutional epimutation that also predisposes to LS (76, 148). 
 
Currently, immunohistochemistry (IHC) analysis of four MMR proteins is recommended for 
all colorectal cancer cases and it can also be considered for the detection of Lynch 
syndrome among endometrial carcinomas (at least when diagnosed at an age of less than 
70 years) internationally (5, 149). Despite these recommendations, it is very clinic- and 
clinician-dependent, deciding which patients will be selected for genetic counseling and 
further IHC testing of the samples.  
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4.2 Hereditary Breast and Ovarian Cancer Syndrome 
Tumor suppressor genes, BRCA1 and BRCA2, involved in the repair of a damaged DNA are 
the genes most often involved in hereditary ovarian cancer causing Hereditary Breast and 
Ovarian Cancer Syndrome (HBOC, OMIM #604370, #612555) and account for 
approximately 14% of the epithelial ovarian carcinomas, and 65 to 85% of all hereditary 
ovarian carcinomas (150-152). Mutations in BRCA1/2 predispose carriers to a high risk of 
breast and ovarian cancer but also other cancers such as prostate cancer in males. The 
cumulative risk for developing ovarian cancer before the age of 80 was recently estimated 
by Kuchenbaeker et al. (153) and found to be 44% in BRCA1 mutation carriers and 17% in 
carriers of BRCA2 germline mutation. Ovarian carcinomas diagnosed in these BRCA1/2 
mutation carriers are generally of the high-grade serous histological type, often an 
aggressive form of ovarian cancer which predominates in the general population as well 
(154).  
 
5 Ovarian and endometrial cancer 
5.1 Closely intertwined epidemiology of endometrial and ovarian carcinoma 
The epidemiology of endometrial and ovarian carcinoma is tightly entangled, including 
highly comparable risk factors as well as age and geography which are correlated with the 
incidence of cancer rates. Many factors, such as a late onset of first menstruation, giving 
birth, breastfeeding and healthy weight reduce the risk for both cancers. On the contrary, 
obesity, late onset of menopause, nulliparity, and heredity increase the risk for endometrial 
and ovarian carcinomas. All these factors contribute to hormonal levels (especially the 
estrogen and progesterone involved in these cancers) and to number of ovulatory cycles 
(155). 
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5. 2 Type I and type II ovarian and endometrial cancer  
Histopathological and epidemiological characteristics underlie the clinical outcome and 
divide both ovarian and endometrial cancer into two major types, designated as type I and 
type II. Tumors of both endometrial and ovarian origin belonging to the type I category as 
being highly similar to each other (156, 157). The differences in genetic, epigenetic and 
gene expression profiles between type I and type II highlight the distinct origin and 
molecular pathways involved and may provide new ways to improve the prognosis due to 
the development of subtype specific treatments (157). The hypotheses of the endometrial 
and ovarian tumorigenesis of type I and II are demonstrated in Figure 4.  
 
Approximately 80 to 85% of all endometrial carcinomas belong to type I category, which 
consists of tumors with low-grade endometrioid histology, that are associated with an 
intense estrogen expression (158), often have a good prognosis, and generally develop 
through hyperplastic endometrial lesions (159). Type II tumors, on the other hand, mainly 
display a serous and clear cell histology, are likely to originate from atrophic endometrium 
and typically have a poor prognosis after their diagnosis (160).  
 
Type I ovarian cancers mainly comprise low-grade serous, low-grade endometrioid, clear 
cell and mucinous carcinomas, whereas high-grade serous is the main histology of type II 
tumors. Type I ovarian tumors typically grow slowly and are thought to originate from 
endometriosis or borderline tumors (157, 161) whereas type II tumors are often aggressive 
and are likely to originate from precursor lesions in fallopian tubes or endosalpingiosis 
(162). In comparison to endometrial type I tumors, which account for the majority of all 
endometrial carcinomas, high-grade serous are the most common histological type and are 
responsible for approximately 70% of all epithelial ovarian tumors (163).  
 
Endometrial and ovarian type I tumors often have mutations in ARID1A, KRAS/BRAF, 
PIK3CA, PTEN, and CTNNB1 (67, 114, 164-166). MSI is a rare feature in normal endometrial 
tissue, but a common finding (13 to 30%) in endometrial carcinoma as well as in preceding 
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hyperplastic tissues, as well as in ovarian type I carcinomas (10%) of sporadic origin (67, 
167-170). Type II endometrial and ovarian tumors frequently harbor mutations in p53 and 
are chromosomally unstable (67, 114, 157, 166). 
 
Figure 4. Hypothesis of endometrial and ovarian tumorigenesis.  
 
5.3 Ovarian cancer 
In the United States, there were 22 440 new ovarian carcinoma cases and 14 080 deaths 
expected in 2017 (171). The early signs of ovarian carcinoma are typically mild and at the 
time of diagnosis, already around 75% of ovarian carcinomas have spread out of the ovaries 
leading to the high fatality rate. Most of the women diagnosed with ovarian cancer die of 
this disease (163).  
 
Ovarian cancer is a highly diverse disease comprising of variable tumors and histological 
cell types within the tumors, which complicates the treatment of ovarian cancer. More than 
95% of ovarian tumors are epithelial, but there are also germ cell and sex cord stromal cell 
tumors. Epithelial ovarian carcinomas are principally classified by the cell type in the tumor 
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into serous (high-grade 70%, low-grade 5%), endometrioid (10%), clear cell (10%) and 
mucinous (3%). The main four histological types of ovarian cancer are shown in Figure 5. In 
addition, undifferentiated and non-malignant borderline ovarian tumors exist (163). It is 
acknowledged that the different histological subtypes are separate entities and should be 
considered as distinct diseases, since they have different clinical presentations, responses 
to treatment, and overall outcome. However, at present, epithelial ovarian cancer is 
treated as a single disease. This is partially attributable to the lack of knowledge of the 
driver molecular events behind each disease. Nonetheless, it is vital to learn more about 
the molecular mechanisms and detect drivers if we are to establish novel and individual 
treatments against all types of ovarian cancer. Other obstacles in the treatment of ovarian 
cancer are the absence of reliable markers for early detection and the acquisition of 
chemoresistance as  treatment progresses (172).  
 
 
Figure 5. The main four histological types of epithelial ovarian cancer. 
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Histology and tumor grade can be used to divide ovarian carcinomas into two different 
categories, namely Type I and Type II (as described above in Chapter 5.2) (157). 
Additionally, ovarian carcinomas are classified into four stages according to the 
International Federation of Gynecology and Obstetrics (FIGO) staging system. The stage 
depends on the invasiveness of the cancer. Accordingly, in stage I, the tumor is confined to 
ovaries or fallopian tube(s), in stage II, the tumor involves one or both ovaries/fallopian 
tube with some pelvic peritoneal extension, in stage III, it has spread to the peritoneum 
outside the pelvis or metastasis to retro-peritoneal lymph nodes has occurred, and by stage 
IV, the metastasis is found in distal organs (173).  
 
5.3.1 Origin of ovarian cancer 
In 1872, Sir Spencer Wells claimed that epithelial ovarian cancer arises from ovarian surface 
epithelial cells and for more than a century, it was believed that the origin of ovarian cancer 
was in the ovary itself (174). But with the latest evidence, it has appeared that the origin 
and early steps of epithelial ovarian carcinoma development take place outside the ovaries. 
There is recent data suggesting that serous ovarian cancer originates from the fallopian 
tubes and endosalpingiosis whereas endometrioid and clear cell ovarian carcinomas 
originate from endometrioid epithelial cells through a process involving atypical 
endometriosis and/or borderline tumors (see Figure 4) (162, 175, 176). It still remains a 
mystery how endometriosis contributes to the development of endometrioid and clear cell 
types of ovarian cancer, but it has been speculated that repetitive damage and repair of 
endometriotic epithelial cells in their microenvironment abundant with free iron which 
induces the production of free radicals and leads to the abnormal growth of these cells 
(177, 178). Although, it has been acknowledged that endometrioid and clear cell ovarian 
carcinomas originate from atypical endometriosis, the importance of alterations in 
endometrial epithelia that contributes to endometriosis has been largely uninvestigated.  
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5. 3.2 Lynch syndrome associated ovarian cancer 
Lynch syndrome is the second most common cause of hereditary ovarian cancer after 
BRCA1/2 (causing HBOC syndrome) and is responsible for 8% to 13% of all hereditary 
ovarian cancers and up to 2 % of all ovarian carcinomas (179, 180). The lifetime risk of 
ovarian cancer in women with LS varies according to the mutation carried by the carrier 
and is 10% in MLH1, 17% in MSH2 and 1% in MSH6 carriers (181) and it occurs typically 
before menopause (7). LS-associated ovarian cancer differs from sporadic ovarian cancer 
in several ways both clinically and histologically. The mean age at diagnosis of ovarian 
cancer in female LS mutation carriers is 45 which is 15 to 20 years earlier than in patients 
with sporadic cases (182).  The histology of ovarian carcinomas is mainly non-serous 
(typically endometrioid or clear cell) and presents as well-differentiated and early stage 
tumors at the time of diagnosis compared to sporadic cases which are typically of serous 
histological type and displayed in advanced tumor stages (182). In addition, more than 20% 
of women with LS have a synchronous endometrial cancer at the time of ovarian cancer 
diagnosis in comparison to sporadic ovarian carcinomas where the frequency of 
synchronous tumors is less than 10% (183, 184). 
 
5.4 Endometrial cancer 
In the United States, it has been estimated that 61 380 new endometrial carcinoma cases 
and 10 920 deaths would occur in 2017 (171). Endometrial cancer is a heterogeneous 
disease from a histopathological standpoint. The vast majority of endometrial carcinomas 
have their origin in the endometrial lining called the endometrium and these cancers are 
referred to as adenocarcinomas. Furthermore, sarcomas exist, which arise mainly from the 
smooth muscle tissue or stromal cells of the uterus (160).  
 
5.4.1 Precursor lesions of type I endometrial cancer and its tumorigenesis 
Tumors of (low-grade) endometrioid histology and categorized as type I are believed to 
develop through hyperplastic lesions likely as a consequence of excessive estrogen 
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stimulation combined with inadequate progesterone levels (185). Endometrial hyperplasia 
means thickening of the endometrium, the lining of the uterus, caused by cellular 
overgrowth. Molecular alterations in KRAS, BRAF and PTEN, a high frequency of MSI, and 
hypermethylation of specific TSGs have been detected in endometrial hyperplastic lesions 
and seem to be early developments in endometrioid endometrial carcinogenesis (186-191).  
 
For 20 years, according to the World Health Organization 1994 (WHO94) and the revised 
WHO2003 schema, the differences in histological complexity of the glandular architecture 
(either simple or complex), the presence or absence of nuclear atypia (atypical and non-
atypical), and the risk of precursor progression into cancer, have been used to divide 
hyperplasias into four categories, namely simple and complex non-atypical as well as 
simple and complex atypical hyperplasia (159, 192-194). Based on several publications, the 
risk of atypical endometrial hyperplasia to progress into carcinoma has been estimated as 
being up to 30%, and therefore these are currently seen as precursor lesions of endometrial 
carcinoma (190, 192). According to these results, in 2014 the WHO decided to classify 
tumors into two categories, namely non-atypical and atypical hyperplasia, and this 
classification is based only on nuclear atypia (WHO2014) (195). This WHO2014 schema is 
currently recommended to be used on categorizing of hyperplasias in Finland. 
 
The categorization of endometrial hyperplasia is not universal and in addition to the 
WHO2014, another schema for endometrial atypical hyperplasia classification exists, 
referred to as endometrial intraepithelial neoplasia (EIN) (196). This schema, developed by 
the International Endometrial Collaborative group, takes into account the clonal origin of 
the lesions as well as all of the criteria and terminology that clearly divide atypical 
hyperplastic lesions into different categories that can be managed differently with a 
specific management protocol recommended for each category. This system classifies the 
precursor lesions into benign (non-atypical hyperplasias which are hormone-dependent 
and these changes are reversible), premalignant (atypical hyperplasias) and malignant 
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(carcinoma) according to the data emerging from histological, genetic, and clinical analyses 
(159, 185, 196, 197).  
 
At present, total hysterectomy (removal of uterus and cervix) is the standard method of 
treating atypical hyperplasia whereas hyperplasia without atypia is treated with 
medication in the majority of the cases (185). Too little is still known about the efficacy of 
the nonsurgical methods, such as progestin-based therapy of atypical hyperplasia, which is 
a desirable alternative in patients who wish to retain fertility and when surgery is not an 
applicable option for the patient (185). 
 
5.4.2 Lynch syndrome associated endometrial cancer 
Around 3 to 5 % of endometrial carcinomas are likely caused by inherited predisposition 
with LS being responsible for most of these cases (198, 199). Moreover, around 10% of all 
early-onset (under age 40) endometrial carcinomas are diagnosed with a deleterious LS 
causing mutation (200). The cumulative incidence of endometrial carcinoma in female LS 
mutation carriers ranges from 43% to 57% depending on the type of mutation (181). 
Compared to the general population, LS-associated endometrial cancer occurs in younger 
women (mean 50 years vs. 68 years), typically before menopause, most (~90%) LS-
associated endometrial carcinomas have an endometrioid histology belonging to type I 
carcinomas (201), and a lower uterine segment involvement is detected in up to 29% of the 
cases compared to less than 5 % in sporadic cases (202). In addition, over 90% of the LS-
associated cases show MSI (203).  There are conflicting results whether the Lynch-
associated endometrial cancer has a worse prognosis compared to the respective sporadic 
cases (204). 
 
The identification of defective MMR system among endometrial carcinoma patients is 
important, because it may enhance prognostication, it can help in guidance of targeted 
therapy and it improves the identification of LS patients (205). It is still a matter of debate, 
whether all endometrial carcinomas should be tested with IHC of MMR proteins. 
Review of the Literature  
  
39 
 
Eventually, as the cost and feasibility of sequencing will become reasonable, all 
endometrial carcinoma cases will be sequenced to detect mutations in the MMR genes. 
Until that day, if resources permit, IHC will become the primary method to detect abnormal 
MMR protein expression in laboratories and hospitals (140). 
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AIMS OF THE STUDY 
In addition to the MMR defects, little is known about the molecular background of LS-
associated ovarian carcinoma. Moreover, molecular changes prior to endometrial and 
ovarian cancer and the sequence of events leading to their appearance remain unsolved. 
The aim of the thesis projects was to identify genetic and epigenetic alterations involved in 
LS-associated and sporadic ovarian and endometrial tumorigenesis. 
The specific aims were: 
 
1. To identify epigenetic, genetic and gene expression alterations in LS-associated and 
sporadic ovarian cancer (I-III) 
2. To investigate epigenetic mechanisms in ovarian tumorigenesis and in particular,  
to discern differences and reveal similarities between LS-associated and sporadic 
ovarian cancer as well as between different histological types of ovarian cancer (II) 
3. To determine the molecular changes that precede endometrial and ovarian cancer 
(III) 
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MATERIALS AND METHODS  
1 Cell lines (II-III) 
Commercial cell lines (endometrial and colorectal cancer cell lines purchased from 
American Type Culture Collection, ATCC, Rockville, USA and ovarian cancer cell lines 
provided by R. Bützow who was involved in all thesis projects) were used in optimization 
and validation of custom MS-MLPA test (specified in section 6.2) as well as in the epigenetic 
drug treatments to detect methylation consequences (specified in section 6.3.1). The DNA 
from cell lines was extracted using the method described by Lahiri and Nurnberg (1991) 
(206). 
 
2 Patient samples (I-III) 
For the studies I and II, all available LS-associated ovarian carcinomas and their respective 
normal samples were identified from the nationwide Hereditary Colorectal Cancer Registry 
of Finland, followed by collection of all available archival FFPE samples. In the third study, 
we took advantage of a surveillance program against gynecological carcinoma which has 
been offered to women with LS in Finland since 1996. Thus, additional newly diagnosed 
cases of LS-associated ovarian cancer as well as all patients diagnosed with endometrial 
carcinoma and/or endometrial hyperplasia and their consecutive aspiration biopsies from 
this surveillance program were identified from the registry and collected. Sporadic samples 
of ovarian (207) and endometrial carcinoma (208), endometrial hyperplasias (189)(and 
original Publication III), reference normal endometria (189, 209) and fallopian tubes (n=22) 
(used in thesis studies I and II) representing histological types common in LS carriers were 
collected from larger sporadic cohorts and studied for comparison. The number of 
specimens included in studies are given in Table 3. For more information of the tumor 
characteristics, please see original publications I-III. A four category system for the 
classification of hyperplasias (simple hyperplasia, SH; simple atypical hyperplasia, SAH; 
complex hyperplasia without atypia, CH; and complex hyperplasia with atypia, CAH) 
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according to WHO2003 (194) was applied for interpretation of hyperplasias because that 
same categorization was being used at the time of diagnosis.  
Table 3. Number of specimens of Lynch and sporadic used in studies.  
 
 
All patient material consisted of FFPE tissue archived in blocks, which had been cut into 4 
μm sections with a microtome, stained with hematoxylin and eosin for visual inspection. 
Areas with over 60% tumor cell coverage were chosen and manually microdissected for 
DNA extraction which was performed according to the customized protocol devised by 
Isola et al. (210). All ovarian and endometrial tissue material was reviewed by a 
gynecological pathologist at the time of diagnosis, and the diagnosis was further re-
evaluated by a collaborator (Bützow R.) when samples were collected.  
 
The studies were approved by the Institutional Review Boards of the Departments of 
Surgery (466/E6/01) and the Obstetrics and Gynecology (040/95) of the Helsinki University 
Central Hospital (Helsinki, Finland) and the Jyväskylä Central Hospital (Jyväskylä, Finland) 
(Dnro 5/2007). The archival specimen collection was approved by the National Authority 
for Medicolegal Affairs (Dnro 1272/04/044/07, original publications I and II) and the 
National Supervisory Authority for Welfare and Health (Valvira/Dnro 
10741/06.01.03.01/2015, original publication III). 
 
A detailed description of patient materials and cell lines as well as methodology used in 
thesis, including information primers and probes, can be found in the original publications 
I-III. A summary of the methods included in the publications see Table 4. 
Ovarian 
cancer
Endometrial 
cancer
Endometrial 
hyperplasias
Normal 
endometrium
Lynch
I 20 − − 49
II 19 − − 7
III 23 35 56 99
Sporadic
I 87 − − 18
II 84 − − 18
III 87 36 76 38
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Table 4. Summary of methods included in thesis.  
 
 
3 Protein expression by immunohistochemistry (I, III) 
Immunohistochemistry (IHC) was used to analyze the protein expression status of the 
specimen. At the beginning of IHC of each protein analyzed, the 4μm FFPE tissue sections 
were deparaffinized with xylene and dehydrated with graded alcohols. After antigen 
retrieval, tissue slides were counterstained with hematoxylin (Mayers HTX, Histolab), 
dehydrated, cleared in xylene, and mounted. IHC was carried out on individual whole-slide 
sections from LS-associated cases and on tissue microarray (TMA) slides containing 
sporadic ovarian and endometrial carcinomas. The slides were scored by two investigators 
and pathologists specialized in gynecology (Bützow R. and Pasanen A.). 
 
3.1 p53 protein (I) 
Expression of p53 protein was analyzed using ultraView Universal DAB Detection Kit with 
Cell Conditioning Solution (CC1, Ventana Medical Systems INC, Tucson, AZ). Anti-p53 
(1:200; clone DO-7, Dako, Glostrup, Denmark) was used as the primary antibody. The 
expression of p53 was regarded as abnormal by two distinct expression profiles; (1) if over 
50% of tumor nuclei were strongly stained indicating overexpression and (2) if expression 
was completely lost but stromal cells stained positive indicating silencing of p53.  
Method Publication
Processing of FFPE samples for DNA extraction and IHC I-III
DNA extraction and quantification I-III
RNA extraction and quantification I
Primer design and DNA sequencing I-III
Mutational analyses I
Single-strand conformation poymorphism analysis (SSCP) I
RNA profil ing by microarray I
Identification of patients with OvCa, EnCa and endometrial hyperplasia from hereditary CRC 
registry of Finland and collection of samples nation-wide
III
Microsatellite instability (MSI) analysis I-III
Immunohistochemistry (IHC) I, III
DNA bisulphite conversion II-III
DNA bisulphite sequencing II-III
Methylation-specific multiplex l igation-dependent probe amplification (MS-MLPA) I-III
Statistical analyses I-III
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3.2 ARID1A and L1CAM proteins (III) 
PT-Module (Lab Vision, CA, USA) was performed for antigen retrieval at 98C°/20 minutes 
using Envision TM Flex Target Retrieval solution, pH 6.1 for ARID1A and pH 9 for L1CAM 
(Agilent technologies, USA). The following antibodies were used: Covance SIG-39110-200 
produced in mouse for L1CAM (1:40 for 20 minutes, CD171, clone 1E11, Covance) and anti-
ARID1A antibody produced in rabbit for ARID1A (1:200 for 20 minutes, HPA005456, 
polyclonal, Lot D104841, Sigma-Aldrich, USA). Autostainer 480 automated immunostainer 
(Lab Vision, CA, USA) was used for staining. Examples of expression and scoring are shown 
in Figure 6.  
 
Figure 6. Examples of normal and abnormal IHC results of ARDI1A and L1CAM proteins. A, ARID1A 
is positive/normal in all nuclei and B, negative/abnormal when there is no nuclear staining of the 
tumor cells but stromal cells show positive expression functioning as an internal control. C, 
Membranous L1CAM staining of cells is scored as negative/normal when less than 10% of tumor 
cells express L1CAM and D, positive/abnormal when more than 10% of tumor cells express L1CAM. 
 
3.3 MMR genes (I, III) 
Whole-slide and TMA sections were immunohistochemically stained with mouse primary 
antibodies detecting MLH1 (anti-MLH1, 1:40, clone G168-15, BD Biosciences/Pharmingen, 
Erembodegem, Belgium), MSH2 (anti-MSH2, 1:60, clone FE11, Calbiochem/Oncogene 
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Research, Darmstadt, Germany), MSH6 (anti-MSH6, 1:60, clone 44/MSH6, BD Biosciences) 
and PMS2 (anti-PMS2, 1:400, clone A16-4, BD Biosciences). MMR expression was regarded 
as negative/abnormal when there was no nuclear staining of tumor cells and the internal 
control (typically stromal cells, tumor infiltrating lymphocytes or endothelium) displayed a 
positive expression. Negative immunostaining of the tumor tissue was interpreted to 
indicate the inactivation of the particular MMR gene. 
 
4 Microsatellite instability (MSI) analysis (I, III) 
MSI was analyzed by DNA fragment analysis using polymerase chain reaction (PCR) with 
mononucleotide repeat markers BAT25 and BAT26. These MSI-markers are sensitive and 
specific and have been shown to define the MSI-status with high accuracy (211, 212). 
Products labeled with fluorescent dyes were sequenced with ABI 3730 Automatic DNA 
Sequencer and GeneMapper 4.0 and 5.0 softwares (Applied Biosystems) were obtained for 
visual interpretation of results. Samples with stable repeat markers were interpreted as 
microsatellite stable (MSS), whereas those with at least one unstable repeat marker was 
considered as MSI.  
 
5 Mutation analysis 
5.1 KRAS, BRAF and PIK3CA (I, III) 
Known hotspot mutations in KRAS, BRAF and PIK3CA were analyzed by exon-specific DNA 
sequencing. Before sequencing, all gene products were amplified by PCR. The primer 
sequences and PCR protocol are described in original Publication I. The PCR products were 
sequenced with ABI 3730 Automatic DNA Sequencer (Applied Biosystems) using BigDye 
Terminator v.3.1 chemistry.    
5. 2 Single strand conformation polymorphism (SSCP) analysis (I) 
SSCP analysis allows two sequences of identical length to be distinguished from each other 
on the basis of their distinct conformations in gel electrophoresis (213). Thus, all the 
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samples identified as positive for the KRAS mutation by sequencing were further 
investigated by SSCP analysis to verify the mutational status against positive reference 
samples carrying known KRAS mutations. Sample DNA amplified in PCR was separated on 
a polyacrylamide gel accompanied with 1 x MDE Gel Solution (Cambrex BioScience 
Rockland Inc., ME, USA) at 3W for 20 hours followed by silver staining of the gel for visual 
detection of DNA. 
 
6 DNA methylation analysis (I-III) 
6.1 Bisulfite modification, direct bisulfite sequencing, and sequencing after 
cloning (II, III) 
Bisulfite modification and direct bisulfite sequencing was used as a method to select a 
representative region for the MS-MLPA probe design and to validate the methylation data 
obtained from a custom designed MS-MLPA test (original publications II and III). In brief, 
600ng of DNA from 13 cancer cell lines, normal colon and endometrial DNA (purchased 
from AMS Biotechnology, UK) as well as blood from a so-called healthy donor were bisulfite 
modified by using EZ DNA methylation Direct™ Kit (Zymo research, CA, USA) following the 
manufacturer´s instructions (version 1.0.7). Bisulfite modification refers to treating of DNA 
with sodium bisulfite (NaHSO3) which deaminates unmethylated cytosine nucleotides 
converting them into a uracil nucleotide, whereas methylation protects cytosine from 
conversion and leaves it intact (214). The MethPrimer-program (215) and manual designing 
when appropriate were used to build bisulfite primers for selected ovarian and endometrial 
cancer related gene promoters. The detailed characteristics of primers and PCR protocol 
can be found in original Publication II. The PCR products were sequenced with Applied 
Biosystems ABI3730 Automatic DNA Sequencer. 
 
Bisulfite sequencing was additionally used after cloning of bisulfite-converted and PCR 
amplified fragment (SFRP2 was used as an example) to prove the quantitative nature of 
MS-MLPA test (see original publication II). PCR amplification products of SFRP2 gene from 
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five cancer cell lines and normal colon and endometrial samples representing distinct types 
of methylation statuses were cloned into Escherichia coli bacterial cells in pCR2.1 TOPO 
vector by utilizing the TOPO TA Cloning System (Invitrogen, USA). After cloning, all 
produced white bacterial colonies were collected, DNA was extracted and sequenced with 
bisulfite sequencing primers. The methylation status of the HhaI restriction site (GCGC) 
chosen to be included in MS-MLPA probe was analyzed for each clone and interpreted as 
either methylated or unmethylated to determine the proportion of methylated DNA. 
Methylation dosage ratio (Dm) values between clones and the MS-MLPA result of SFRP2 
were concordant.   
 
6.2 MS-MLPA (I-III) 
All methylation data produced from patient samples was conducted by methylation-
specific multiplex ligation-dependent probe amplification (MS-MLPA) test (Figure 7), first 
introduced by Nygren et al. in 2005 (216).  MS-MLPA test is based on probes that contain a 
restriction site (GCGC) for the methylation-sensitive endonuclease HhaI (Promega, USA), 
which binds to the unmethylated CpG dinucleotide of a GCGC site and subsequently digests 
the site. If the GCGC is methylated, then the site stays undigested and will generate a signal 
peak in PCR. All MS-MLPA analyses involving TSGs were conducted according to the 
manufacturer´s protocol (217) using 100 to 250ng of DNA extracted from FFPE samples. 
The PCR products were separated by capillary electrophoresis performed with ABI 3730 
Automatic DNA sequencer (Applied Biosystems, USA) and analyzed by GeneMapper 4.0 
and 5.0 genotyping software (Applied Biosystems). For each sample analyzed, the MS-
MLPA method produces a Dm-value which is calculated as described in Gylling et al. (218). 
The Dm-value varies between 0 and 1 corresponding to the frequency of methylated DNA 
in the specific GCGC site analyzed.  
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Figure 7. General outline of the MS-MLPA method. The probe targeting a specific gene promoter 
consists of two oligonucleotides (left and right oligo probes, LPO and RPO), each probe containing a 
universal primer sequence (black), a hybridizing sequence (blue), and a stuffer sequence (green) 
when needed. A, the method starts with denaturation of DNA and hybridization of the probes to 
their target sequences. B, ligation and digestion are performed in two tubes: The first tube both 
ligation and digestion take place whereas in the second tube only ligation reaction is carried out (not 
shown in the figure). In the first tube, only the probe pairs that target a methylated GCGC site will 
ligate, since the HhaI restriction enzyme does not recognize and digest the site. If the target site is 
unmethylated, HhaI enzyme will digest the site and the LPO and RPO will not be ligated. C, only 
ligated probes are exponentially amplified in subsequent PCR and show as peaks in the 
electropherogram. Black dots indicate the reference probes, that do not contain HhaI restriction site 
and will be amplified and generate a peak in ligated and digested reactions. A star indicates the 
target DNA sequence and shows a peak in the digested sample only when the target DNA is 
methylated. 
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Commercial MS-MLPA test (SALSA ME001-C2 Tumour suppressor 1, MRC Holland, The 
Netherlands) was applied to analyze methylation patterns of 24 general tumor suppressor 
genes (TSGs) (219) often known to be methylated in several cancer types. The threshold 
Dm-value of 0.15 or above was considered to represent methylation as previously 
described (218) for all commercial TSGs except for CDKN2B (Dm cut-off = 0.34), which was 
noticed by MRC-Holland to give higher values than expected.  
 
A custom MS-MLPA test was designed to detect abnormal methylation of 11 TSGs and two 
miRNA genes (genes specified in original publication II) often methylated in endometrial 
and ovarian cancer. The methylation patterns of CpG islands in promoters of selected genes 
containing a GCGC site were first investigated by bisulfite sequencing of cancer cell line and 
normal sample DNA followed by designing of custom MS-MLPA probes that were optimized 
according to the results obtained from bisulfite sequencing to target representative HhaI 
restriction sequences (GCGC) and by bacterial cloning of SFRP2 gene as described briefly 
above and more detailed in original publication II. The custom MS-MLPA probes were 
designed following the instructions from MRC Holland (217). CpG islands of selected genes 
were detected using EMBOSS CpG Plot software (220). Custom probes were combined with 
SALSA MLPA kit P-300-B1 human DNA reference-2 (221) to carry out MS-MLPA reactions. 
Since the baseline level for methylation that distinguishes tumor from normal depends on 
the normal tissue as well as probe analyzed, the thresholds for methylation were calculated 
individually for each endometrial and ovarian cancer related gene (see original Publications 
I and III). In brief, the thresholds for each gene were calculated separately for LS-associated 
and sporadic case according to average methylation levels in normal endometrium (for 
comparison of non-serous samples) and in fallopian tubes (for comparison of serous 
samples) plus 1 standard deviation. 
 
6.2.1 LINE-1 hypomethylation analysis (I) 
A custom-made MS-MLPA test designed by Pavicic et al. (222) was used to measure 
hypomethylation from LS-associated ovarian carcinomas and their respective normal 
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samples when available as well as from sporadic ovarian carcinomas by using 50 to 100 ng 
of FFPE DNA. This custom MS-MLPA test contains three LINE-1-specific probes with HhaI 
restriction site and is combined with the SALSA MLPA kit P300-A1 Human DNA Reference-
2 (221). The test was carried out following the customized standard MS-MLPA protocol, 
defined by Pavicic et al. (222).  
 
6.3 Expression based methods 
6.3.1 Cell culturing and epigenetic drug treatments 
Gene expression can be regulated by epigenetic modifications, such as DNA methylation 
and histone acetylation. Chemical agents, 5-aza-2'-deoxycytidine (5-aza-dC) and 
trichostatin A (TSA) can be used to modify these epigenetic alterations and change the 
regulative stage of a protein. 5-aAza-dC functions as a strong inhibitor of methyltransferase 
causing demethylation and reactivation of epigenetically inactivated genes (223). TSA, on 
the other hand, inhibits HDAC activity and leads to an opening of the chromatin structure 
(224, 225). 5-Aza-dC and TSA have been reported to exert a synergistic effect in the re-
activation of expression of genes epigenetically silenced by methylation (226, 227). 
Therefore, both chemical agents were used in order to achieve the highest possible 
reactivation state of genes silenced by promoter methylation and further to confirm the 
methylation consequences of selected genes.  
 
Different cell lines were chosen for treatments to serve as models for different types of 
carcinomas and MMR status. The cell lines were cultured as described in the supplier´s 
instructions (ATCC, Rockville, MD, USA) and then treated according to protocol by Derks et 
al. (228) with 5-aza-dC (1μM, Sigma, A3656) and TSA (300nM, Sigma, T1952) for 96h and 
18h, respectively. All drug treatments were done in duplicate to verify the effect of the 
treatment on the cell line. After treatments, the cell line DNA was extracted using the 
standard protocol by Isola et al. and total RNA was isolated with miRNeasy mini kit (Qiagen, 
CA, USA). The performance of drug treatments was verified by comparing the results before 
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and after treatment by investigating the promoter methylation of selected TSGs using 
SALSA MS-MLPA ME001-C1 (219) test.  
6.3.2 Genome-wide RNA expression profiling of cell lines (I)  
Genome-wide mRNA gene expression analysis was accomplished using Affymetrix Human 
Genome U133 plus 2.0 GeneChip® microarrays (Affymetrix, Santa Clara, CA) whereas 
miRNA expression was analyzed using Agilent´s human miRNA microarrays (8 x 15 K, Agilent 
Technologies, G4470B). RNA isolated from treated and untreated cell lines as well as 
respective normal samples (Amsbio, Abingdon, UK or extracted from fresh-frozen tissues 
obtained from national hospitals) were amplified, labeled and hybridized as characterized 
in Nymark et al. (229). Array image and fluorescent signals were analyzed using GeneChip 
operating software (from Affymetrix) for mRNA data whereas fluorescent signal intensities 
from miRNA expression array were calculated according to the Feature Extraction software 
(version 10.7.3.1, Agilent). 
Microarray data analysis was carried out by GeneSpring GX software, version 12 (Agilent 
Technologies, Santa Clara, CA) for both mRNA and miRNA expression. The following 
parameters were established to evaluate distinct mRNA and miRNA expression patterns 
between treated and untreated cell lines and normal samples: (1) mRNA expression was 
RMA normalized whereas quantile normalization was used for miRNA data, (2) the 
statistical significance of gene expression changes was identified by moderated t-test 
integrated with Benjamini and Hochberg correction for multiple testing and (3) filters based 
on p-value cut-off of 0.05 and fold change cut-off +/-1.5 were chosen to identify distinct 
expression. 
 
7 Statistical analyses (I-III) 
Statistical evaluations were performed using SPSS software, versions 20.0 and 22.0 (IBM® 
SPSS® Statistics, Inc. Chicago, IL, USA) as well as using Vassarstats programs (230). Fisher´s 
exact test was applied to calculate frequency data in pairwise comparisons of gene 
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expression status as well as MMR status (two-tailed P-values) and adjusted for multiple 
comparisons by Bonferroni correction when appropriate. Comparisons between two 
groups involving Dm-values of specific genes or numbers of methylated genes, Shapiro-
Wilk test was implemented first to test if the data were normally distributed. Student´s T-
test was applied for normally distributed samples and Mann-Whitney U test for samples 
not normally distributed. The non-parametric Kruskal-Wallis test with pairwise 
comparisons was applied when analyzing statistical significance of methylation changes 
between multiple categories of endometrial specimens. Kruskal-Wallis was chosen because 
either all groups did not reach the homogeneity of variances studied by Levene´s test or 
were not normally distributed. P values < 0.05 (2-tailed) were considered significant. 
Pearson product-moment correlation coefficient for normally distributed (tested by 
Shapiro-Wilkins test) data and Spearman rank correlation coefficient for data not normally 
distributed was applied to test statistical significance between methylation and expression 
correlation.  The detailed description of statistical analyses used for gene expression data 
are depicted above in section 6.3.2. 
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RESULTS 
1 Novel molecular profile of Lynch syndrome associated ovarian cancer (I-III) 
At the beginning of this thesis project in 2011, rather little was known about the exact 
molecular background of LS-associated ovarian cancer and in general, the origin of ovarian 
cancer was just starting to be revealed. The clinical and histological differences between 
LS-associated and sporadic ovarian cancer had been acknowledged but the underlying 
genetic and epigenetic causes of these differences other than MMR defects remained a 
mystery. It was particularly interesting to examine whether there are molecular differences 
that can explain the better survival of ovarian cancer in LS-associated versus sporadic 
ovarian cancer (183). Prompted by this lack of knowledge, we decided to investigate 
established genetic and new epigenetic markers involved in ovarian cancer from LS-
associated ovarian carcinomas and compare results to cases from sporadic cohorts with 
corresponding histological types. Among the genetic markers studied, there were the 
known hotspot mutation sites from KRAS, BRAF, and PIK3CA which were identified by exon 
specific sequencing, whereas immunohistochemistry (IHC) was used to detect aberrant 
protein expression of the MMR, p53, ARID1A, and L1CAM genes. Additionally, MSI analysis 
was carried out to verify the MMR status and to detect MMR deficient cases missed by 
MMR IHC. Epigenetic analysis was carried out by investigating promoter methylation of 37 
TSGs shown to be involved in tumorigenesis. 
 
All available cases with ovarian cancer were identified from the nationwide Hereditary 
Colorectal Cancer Registry of Finland and collected as part of the project. Overall, 14 cases 
of endometrioid and 9 cases of clear cell ovarian carcinomas were collected from 22 MMR 
mutation carriers and the results were compared to 39 and 28 cases of clear cell and 
endometrioid type of ovarian cancer, respectively, from sporadic cases. Additionally, LS-
associated cases included two serous cases (one low- and one high-grade). For comparison 
of the results from carcinomas, 18 normal unrelated endometrial samples (the expected 
origin of endometrioid and clear cell ovarian carcinomas) were analyzed. The sporadic high-
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grade serous category was included in the analysis in original Publications I and II. The next 
sections will concentrate on the findings from non-serous (endometrioid and clear cell) 
histological types of ovarian cancer, which are the prevalent histological types among LS 
mutation carriers.  
 
1.2 Genetic profile of Lynch syndrome associated ovarian cancer (I, III) 
1.2.1 Deficient MMR status is a key feature of ovarian carcinomas from Lynch mutation 
carriers (I-III) 
Lynch patients inherit one inactive allele of a MMR gene (or EPCAM gene in rare cases). 
One inactive gene copy in all of the cells of an individual´s body predisposes the individual 
to a high risk of cancer. However, in order for tumor development to start, a second 
somatic alteration of the other parental allele needs to occur in the target tissue (140). 
Deficient MMR status of a sample marks inactivation of the wild type allele by somatic 
alteration. Accordingly, we regarded MMR status deficient if MSI was found by 
microsatellite analysis, or a loss of MMR protein expression detected by IHC, or both. 
Deficient MMR is a key feature of LS-associated ovarian carcinomas but also a common 
characteristic of type 1 ovarian cancer of sporadic origin (231). All (23/23, 100%) LS-
associated type I ovarian carcinomas were MMR deficient (see Figure 8 and 9). In sporadic 
ovarian carcinomas, MMR-deficiency was detected in 14% (4/28) of endometrioid and 15% 
(6/39%) of clear cell ovarian carcinomas. The difference was statistically significant 
(P<0.001) between LS and sporadic cases of corresponding histological types. 
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Figure 8. Frequencies of abnormal status of p53, MMR, ARID1A, and L1CAM expression in LS-
associated versus sporadic type I ovarian cancer. Abbreviations: OvE, endometrioid ovarian cancer; 
OvCC, clear cell ovarian cancer. 
 
1.2.2 p53, ARID1A and L1CAM expression profiles in LS-associated ovarian cancer (I, III) 
A TSG p53 is often abnormally expressed in several cancer types and is a typical feature of 
type II (mainly high-grade serous) ovarian carcinomas (114). Normal expression of p53 was 
detected in all LS-associated endometrioid (12/12) and clear cell (7/7) ovarian carcinomas 
whereas abnormal expression was present in 30% (8/27) of endometrioid and 18% (7/39) 
of clear cell ovarian carcinomas of sporadic origin as demonstrated in Figures 8 and 9. 
When endometrioid and clear cell histological types were combined and the results were 
compared between LS (0%, 0/19) and sporadic cases (23%, 15/66), sporadic cases showed 
a significantly higher frequency of aberrant p53 expression (P=0.035) in non-serous tumors. 
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ARID1A, a tumor suppressor and a subunit of SWI/SNF chromatin remodeling complex, is 
often mutated in type 1 ovarian tumors, irrespective of MMR-status (114, 232). 
Surprisingly, LS-associated ovarian carcinomas revealed an exceptionally high frequency of 
aberrant ARID1A expression. All LS-associated clear cell (9/9) and 86% (12/14) of the 
endometrioid ovarian carcinomas had lost their ARID1A expression which was in striking 
contrast to sporadic cases where ARID1A expression was absent in none of the clear cell 
(0/39) and in only 11% (3/28) of the endometrioid ovarian carcinomas. The differences 
between different histological types of LS and sporadic ovarian tumors of corresponding 
histological types were significant (P<0.001) as shown in Figure 8. 
 
Overexpression of L1CAM is connected to invasion and metastatic potential in cancer and 
aberrant expression of L1CAM has been detected in endometrial and ovarian cancer by 
several studies (233-237). Compared to the high prevalence (86% – 100%) of aberrant 
ARID1A expression and MMR defects in LS-associated ovarian carcinomas, L1CAM 
aberrations were less frequent. L1CAM overexpression showed the highest frequencies in 
ovarian clear cell carcinomas: 43% (3/7) in LS-associated and 26% (10/39) in sporadic clear 
cell ovarian carcinoma compared to 15% (2/13) and 18% (5/28) of endometrioid ovarian 
carcinomas in LS-associated and sporadic cases, respectively (A.N. et al. unpublished data). 
The differences between LS and sporadic cases were not statistically significant which in 
part may reflect the small sample series (Figure 8). Although, overexpression of L1CAM has 
been associated with a dismal prognosis in ovarian cancer (235) in a recent publication by 
Soovares et al. (207) the dismal prognosis was shown to be associated only with 
endometrioid but not in clear cell type of ovarian cancer. According to results from 
Soovares et al. (207) our finding of frequent L1CAM overexpression in LS-associated clear 
cell ovarian cancer is in agreement with the high survival  among LS-associated ovarian 
carcinomas (8, 183). Moreover, the only two endometrioid ovarian carcinomas that were 
detected with aberrant L1CAM expression were characterized as grade 2 carcinomas, thus 
showing a higher grade (A.N. et al. unpublished data). 
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Figure 9. Genetic profile of LS-associated vs. sporadic non-serous ovarian carcinomas. 
 
1.2.3 KRAS, BRAF and PIK3CA mutations in LS-associated ovarian carcinomas (I) 
Type I ovarian carcinomas often show mutations in KRAS, BRAF and PIK3CA genes (157, 
238). As a unique feature of LS-associated ovarian carcinomas, these completely lacked 
mutations in KRAS exon 2 and BRAF V600E. The BRAF mutations were also absent in 
sporadic endometrioid and clear cell ovarian carcinomas, instead KRAS mutations were 
detected in 11% (3/27) of endometrioid and 8% (3/37) of clear cell ovarian carcinomas as 
shown in Figure 9. The observed differences between LS and sporadic ovarian carcinomas 
did not reach statistical significance.  
 
PIK3CA mutations are detected in 20 to 40% of sporadic endometrioid and clear cell (non-
serous) but are rare in serous ovarian carcinomas according to the literature (239, 240). 
Our results were in agreement with previous findings from sporadic tumors: PIK3CA 
mutations were present in similar frequencies in LS-associated (6/19, 32%) and sporadic 
(24/67, 36%) non-serous ovarian cancer, but only in 5% (1/20) of sporadic serous ovarian 
carcinoma. Thus, hotspot mutations of PIK3CA seem to be a characteristic of non-serous 
histological type and common regardless of hereditary or sporadic background (Figure 9).  
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The lack of p53 expression aberrations and KRAS mutations but frequent detection of 
PIK3CA alterations agree with the good prognosis in LS ovarian carcinoma patients, since 
p53 abnormalities and KRAS mutations have been shown to associate with advanced stages 
and poor prognosis, whereas PIK3CA mutations which activate P13K/AKT/mTOR pathway 
are connected to a propitious prognosis in ovarian cancer (25, 239-241). In addition, our 
data resembled the genetic background of LS-associated colorectal carcinomas, which also 
have fewer p53 expression aberrations (242), BRAF mutations (243), better stage-specific 
survival compared to sporadic cases and also harbor PIK3CA mutations in approximately 
20% of the cases (137).  
 
1.3 Epigenetic profile of LS-associated ovarian cancer (I-III) 
In addition to genetic alterations, DNA methylation analyses (by MS-MLPA) were motivated 
as epigenetic changes provide fingerprints of cancer cell origins (244), are histology-specific 
(67), and likely to promote tumorigenesis in MMR deficient cells. Hypermethylation of TSG 
promoters and genome-wide hypomethylation are likely to drive tumorigenesis, since they 
arise in early steps of tumor development (83). Therefore, it is important to look deeper 
into the epigenetic changes and differences between different backgrounds and 
histological subtypes of ovarian carcinoma in order to enhance diagnosis, treatments and 
survival of the patients. 
 
1.3.1 Hypermethylation of specific gene promoters is a frequent event in LS ovarian 
tumorigenesis (I-III) 
A panel of epigenetic markers to study hypermethylation (13 endometrial and ovarian 
cancer related and 24 general TSGs often methylated in cancer) was chosen for sample 
profiling. In addition to commercial MS-MLPA assay including 24 TSGs often methylated in 
several cancer, we wanted to design a custom test including genes that would be more 
specific for endometrial and ovarian cancer. Briefly, gene candidates that would be highly 
informative epigenetic markers specifically for endometrial and ovarian carcinomas were 
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identified from the literature and by expression profiling of cancer cell lines treated with 
demethylating chemicals. After evaluation for the most informative markers, a custom MS-
MLPA test was designed to include 13 genes. The selected gene candidates fulfilled two 
key prerequisites: (1) Abnormal methylation at the gene promoter can be used as a marker 
of a malignant process based on literature and (2) methylation was shown to correlate with 
expression by expression profiling or by literature. MS-MLPA was chosen as a method to 
investigate promoter methylation, because it can be used to analyze low quality and 
fragmented DNA extracted from FFPE tissue blocks. Normal endometrial tissue specimens 
(18 non-related cases) were used as a reference. All promoters of genes included in the 
studies except the promoters of WT1 and CABLES1 (showing low levels of methylation in 
tumor and normal samples) as well as let-7-3a (oncogenic miRNA showing high methylation 
levels in tumor and normal samples) displayed a low degree of methylation in normal 
endometrial tissue and increased methylation levels in non-serous (endometrioid and clear 
cell) ovarian tumors. 
 
The highest hypermethylation frequencies were detected in genes RSK4, PROM1, and 
MIR34B in LS-associated clear cell ovarian carcinomas among all histological types and LS 
and sporadic origin. Moreover, LS-associated endometrioid ovarian carcinomas resembled 
those found in sporadic cases. RSK4, SPARC, PROM1, HOXA10, HOXA9, WT1-AS, SFRP2, 
OPCML, and MIR34B were frequently hypermethylated in LS-associated and sporadic 
ovarian non-serous tumors compared to normal endometrial tissue.  
 
LS-associated and sporadic endometrioid and clear cell ovarian carcinomas were combined 
for analysis of clinical correlations. One interesting finding was made according to grade 
analysis with endometrioid ovarian carcinomas, where Dm values of RSK4, SPARC and 
HOXA9 were shown to decrease together with increasing grade of tumors, showing a shift 
towards the characteristics of high-grade serous tumors (see original publication II for more 
information). Therefore, lower methylation levels among these three genes may predict a 
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more aggressive (high-grade) phenotype within endometrioid carcinomas which generally 
have a favorable prognosis (245). 
 
The same trend of high hypermethylation frequencies of selected genes in non-serous 
tumors of LS and sporadic background were observed when analyzing the methylation of 
24 general TSGs using commercial MS-MLPA test. Figure 10 demonstrates the methylation 
profiles of the TSGs most frequently methylated among Lynch-associated ovarian tumors 
compared to normal endometrium.  
 
Promoter methylation of TSGs has previously been shown to be a common feature of LS-
associated endometrial, colorectal, gastric, urinary tract, brain and breast tumors using the 
same commercial MS-MLPA assay (189, 218, 246-249). The former studies have highlighted 
that TSG promoter methylation levels and the average number of methylated genes are 
tissue specific, and additionally, hereditary background affects the methylation profile 
(246-248). Agreeing with results from other LS-associated tumors, methylation profiles of 
TSGs in ovarian carcinomas varied depending of the histological type of tumor and 
hereditary vs. sporadic origin. The most frequently methylated TSGs among 24 were APC, 
RASSF1, TP73, and CDH13 and hypermethylation of these genes appears to be a common 
feature of LS-associated and sporadic non-serous ovarian carcinomas. All these genes, 
except TP73 were also frequently methylated in LS-tumors of different types from other 
studies (189, 218, 246-249). Moreover, Strathdee et al. (250) detected hypermethylation 
of TP73 in sporadic ovarian carcinomas, but the frequencies were rather low (13%). 
Although the frequencies of hypermethylated promoters of TP73 and CDH13 were high in 
tumors, the frequencies were high in normal endometrial tissue of Lynch and sporadic 
origin as well, and therefore no significant differences were detected between tumor and 
normal tissue (see Figure 10). Since TP73 and CDH13 were often methylated already in 
normal endometrium from LS-associated cases, it may indicate that the promoters of these 
genes become hypermethylated and silenced early in ovarian (and endometrial) tumor 
development.  
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An interesting observation among LS-associated ovarian tumors, was the finding that LS-
associated ovarian carcinomas displayed the highest number of hypermethylated genes 
(4.2/24) and the lowest levels of LINE-1 hypomethylation (Dm=0.91) as compared to the 
results from all other LS-associated tumors collected from 8 different organs and analyzed 
using the same techniques (218, 222, 247, 248). These findings suggest that TSG 
hypermethylation is an important part of ovarian tumorigenesis, especially in LS. 
 
BRCA1 and BRCA2 are among the most investigated genes in ovarian cancer due to their 
important role in hereditary and sporadic types of the disease (150-152). Promoter 
methylation of BRCA1 is thought to be the cause for the loss of BRCA1 expression in 
sporadic ovarian cancer (251). Complete or partial silencing of the BRCA1 gene due to 
promoter methylation has been observed in 15% of ovarian tumors with a sporadic 
background and the methylation has been shown to be more frequent among advanced 
stages (II and III) and serous histological type of ovarian cancer than in stage I and non-
serous tumors (250, 252, 253). In contrast to BRCA1 methylation profile in ovarian cancer, 
BRCA2 does not seem to be differentially methylated in ovarian cancer compared to normal 
tissue (254). BRCA1 and BRCA2 were included in the 24 TSG panel, but no methylation in 
either of the gene promoters were detected among LS-associated or sporadic ovarian 
carcinomas of different histological types. Our sporadic series included a serous set of 
ovarian carcinomas (n=20) but no signs of methylation were detected in these carcinomas. 
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Figure 10. TSG methylation profiles of the most interesting methylation markers in LS-associated 
endometrioid and clear cell tumors vs. normal reference endometrial tissue. Cut-off Dm-values are 
gene-specific and can be found in original publications I and III. Only TSGs that showed methylation 
above its cut-off level in at least 35% of tumors of any histological group were included in this 
comparison. Asterisks denote significantly elevated methylation in tumor vs. normal endometrium 
by t-test for independent samples. 
 
1.3.2 Hypomethylation is not a feature of LS ovarian tumors (I) 
Decrease in methylation (hypomethylation) of highly repetitive sequences, such as LINE-1, 
may activate oncogenes and oncogenic microRNAs (98). Moreover, several studies have 
linked LINE-1 hypomethylation in hereditary and familial cancer (222, 255, 256), the level 
of LINE-1 hypomethylation can distinguish colorectal carcinoma subgroups (256), and it has 
been shown to arise early in ovarian carcinoma development (90). Motivated by these 
Results 
  
63 
 
findings, we wanted to investigate LINE-1 methylation levels in normal and tumor tissues 
from LS-associated and sporadic ovarian carcinoma patients by using custom MS-MLPA 
method designed by Pavicic et al. (222). LINE-1 is highly methylated in normal cells and 
often hypomethylated in tumor cells (96) and hypomethylation of this elements has been 
shown to increase in all histological types of ovarian cancer from normal tissue towards 
cancer (235, 257). However, in contrast to hypermethylation profiles, hypomethylation 
does not seem to differ among different histological types of sporadic ovarian cancer (258). 
Our findings of sporadic ovarian carcinomas are in line with the previous reports, since 
decreased methylation of LINE-1 compared to normal corresponding tissue was a 
characteristic of all histological types of sporadic ovarian cancer, and the differences 
between tumors of all histological types compared to the respective normal tissue were 
statistically significant. On the other hand, no decrease in the average level of methylation 
was detected between LS-associated ovarian endometrioid carcinomas (n=12, Dm=0.90) 
and corresponding normal endometrial tissue (n=49, Dm=0.90) and LINE-1 
hypomethylation was even increased in clear cell carcinomas (n=7, Dm=0.94) compared to 
normal tissue from LS mutation carriers. Thus, our results emphasize that genome-wide 
hypomethylation is a characteristic of sporadic ovarian cancers, whereas the absence of 
prominent hypomethylation of LINE-1 may be a feature of LS-associated ovarian 
carcinoma. The same observation was made later by Sahnane et al. (256). 
 
2 Molecular alterations in progressive endometrial specimens prior to 
endometrial and ovarian cancer (III) 
The molecular aberrations and the sequence of events that lead to endometrial and ovarian 
tumorigenesis are unknown. In order to investigate early steps in these cancers, we took 
advantage of a lifelong surveillance program against gynecological cancer provided since 
1996 in Finland (13) for women with LS. We collected all consecutive endometrial 
aspiration biopsy specimens, tumor tissue and respective (pre-malignant) hyperplastic and 
normal endometrial tissue from hysterectomy and salpingo-oophorectomy from patients 
identified with endometrial and/or ovarian cancer or endometrial hyperplasia as endpoint. 
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Altogether 213 samples were obtained from 66 LS mutation carriers and were 
supplemented with 197 histology-matched specimens from sporadic cohorts. The samples 
were examined using markers known to be involved in endometrial and ovarian 
tumorigenesis, including protein expression of ARID1A, L1CAM and MMR proteins, MSI 
analysis and TSG hypermethylation of the 24 general TSGs often methylated in cancer using 
commercial MS-MLPA tests (ME-001-C2) and additional 7 markers (RSK4, SPARC, PROM1, 
WT1, CABLES1, HOXA10 and HOXA9) often methylated in endometrial and ovarian cancer 
using custom designed MS-MLPA assay. 
 
Both LS and sporadic series of endometrial specimens revealed accumulation of genetic 
and epigenetic changes along with the increasing level of histological abnormality of 
hyperplastic lesions. Figure 11 demonstrates that loss of ARID1A expression and MMR-
deficiency were the most prominent genetic alterations, whereas increasing levels of TSG 
hypermethylation from low malignant potential to high malignant potential lesions 
illustrated epigenetic aberrations. Loss of ARID1A expression, deficient MMR and TSG 
hypermethylation were characteristics of early tumorigenesis, whereas L1CAM was not a 
particularly informative marker. The loss of ARID1A was detected already in one case of LS-
associated complex hyperplasia without atypia (CH) 25% (1/4), and appeared in 20% of 
cases with complex atypical hyperplasia (CAH) of LS (6/30) and sporadic (4/20) origin. Even 
earlier changes were MMR-deficiency and TSG promoter methylation which were detected 
already in histologically normal endometrium of LS-associated cases (Figure 11). The 
presence of MMR-deficiency in histologically normal endometrium in 12% (12/99) of LS 
specimens compared to 0% (0/38) of sporadic cases was a remarkable feature of LS (the 
difference was statistically significant between LS and sporadic, P=0.037). An analysis of 
consecutive endometrial samples showed that in a few cases, MSI was detectable several 
years before endometrial cancer (see LEC1, original publication III), ovarian cancer (LOC20, 
original publication III) or endometrial hyperplasia (LCAH5, original publication III). All the 
cases in which CAH was detected 1 to 9 years before ovarian or endometrial carcinoma 
diagnosis were MMR deficient (7/7 = 100%). Interestingly, also one case with CH (1/1) and 
Results 
  
65 
 
67% (2/3) of the patients with simple hyperplasia (SH) diagnosis 1-2 years before 
carcinoma, were shown to be MMR deficient. Thus, MMR deficiency in hyperplastic 
endometrial specimens may predict endometrial or ovarian tumor development in LS 
patients.  
 
 
 
Figure 11. Occurrence of ARID1A, L1CAM and MMR aberrations (upper panel) and average numbers 
of methylated endometrial and ovarian cancer related TSGs and 24 general TSGs (lower panel) in LS-
associated and sporadic endometrial specimens as part of progressive endometrial and ovarian 
tumorigenesis. Alterations in ARID1A, L1CAM and MMR in ovarian cancer are demonstrated in 
Figure 8. The number of samples studied in each category is given below the bar graphs. P-values by 
Fisher´s exact test for LS vs. sporadic comparisons test are indicated on the right. Only significant 
values are shown. Abbreviations: N/A, result not available; EnCa, endometrial carcinoma; OvCa, 
ovarian carcinoma. 
 
Another intriguing finding made by investigating endometrial progressive specimens from 
LS-associated and sporadic cases was that they could be divided into three categories 
Results 
  
66 
 
according to increasing abnormalities in ARID1A expression, MMR deficiency, and TSG 
promoter methylation, based on the significant differences between combined groups 
(detailed categorization explained in original publication III). The categories comprised of 
normal endometrium (NE) and simple hyperplasia (SH) (I), complex hyperplasia with (CAH) 
or without atypia (CH) (II), and endometrial cancer (III). The current classification devised 
by WHO2014 combines non-atypical SH and CH and treats them as non-neoplastic forms 
for endometrial cancer and only considers CAH (and SAH) as potential premalignant forms 
of endometrial cancer. In contrast to WHO classification, our analysis with different genetic 
and epigenetic markers, CH and CAH were molecularly indistinguishable.   
 
2.1 Molecular comparison of synchronous LS-associated endometrial and 
ovarian carcinoma specimens (III) 
In approximately 20% (201, 259) of LS-associated and 5 to 10% of sporadic cases (260, 261), 
endometrial and ovarian carcinomas are diagnosed concurrently, raising the question of 
whether the two carcinomas arise independently as primary carcinomas or one is a 
metastasis of the other.  
 
Among the samples collected from LS mutation carriers with endometrial and/or ovarian 
carcinoma, 13 cases with synchronous carcinomas were identified. We utilized this unique 
synchronous sample set to investigate the relationship between ovarian and endometrial 
carcinogenesis in LS. In total, nine pairs of synchronous endometrial and ovarian 
carcinomas, 3 cases with bilateral (and synchronous) ovarian carcinomas and one 
synchronous case of endometrial and endocervical adenocarcinoma were identified. Figure 
12 illustrates the molecular findings case by case of the synchronous tumors. Synchronous 
carcinomas always shared identical MMR-status (13/13) and ARID1A expression when the 
result was available from both cases (11/11). Moreover, TSG hypermethylation profiles 
showed a high intra-pair concordance and an average of 4.4 (57/13) TSGs per synchronous 
tumor pair were concordantly methylated among 31 TSGs investigated. The most 
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frequently concordantly methylated TSGs among synchronous tumor pairs were CDH13 
(75%, 9/12), RSK4 (54%, 7/13), SPARC (46%, 6/13), HOXA10 (46%, 6/13), and RASSF1 (42%, 
5/12). Interestingly, the expression of L1CAM, an adhesion molecule involved in metastasis 
(235, 262), was abnormal in 6/14 (43%) of the carcinomas included in synchronous ovarian 
and endometrial tumor pairs, compared to 3/25 (12%) of independently arisen ovarian and 
endometrial tumors (P=0.047) (A.N. et al. unpublished data). Our molecular findings from 
synchronous gynecological tumors in LS mutation carriers strongly suggest that each pair 
has a shared origin with one tumor likely to arise as the metastasis of some other tumor.  
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2.2 Closely entangled pathways of endometrial and ovarian tumorigenesis (III) 
Molecular characteristics of endometrial hyperplasias preceding or coinciding with ovarian 
carcinoma from LS patients are shown case by case in Figure 13. In patients with 
endometrioid ovarian cancer CAH was diagnosed prior or concurrently with ovarian cancer 
in 50% (7/14) of the cases and in 22% (2/9) of the cases with clear cell ovarian cancer. The 
high extent of similarity of molecular markers (mainly MMR status and hypermethylation 
of specific genes) was detected between ovarian cancer and hyperplastic lesions, 
suggesting that ovarian cancer may also develop in a stepwise manner from endometrial 
hyperplasia. Only 38% (3/8) of the cases with ovarian cancer and concurrent CAH were 
diagnosed with endometrial carcinoma as well. Cases LOC1 (CAH detected three years 
before ovarian cancer) and LOC13 (CAH detected concurrent with ovarian cancer) highlight 
molecular similarity between CAH and ovarian cancer. These findings together with the 
common background of synchronous endometrial and ovarian cancer in LS mutation 
carriers as described above suggest that type I endometrial and ovarian tumorigenesis may 
be molecularly even more entangled than previously appreciated.  
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DISCUSSION 
1 Developmental model of ovarian and endometrial tumorigenesis in Lynch 
syndrome and sporadic cases 
1.1 Overview based on currently available data 
The epidemiologies of ovarian and endometrial cancer are closely entangled which is 
probably attributable to similarities in the hormonal, immune system-related, and 
inflammation mechanisms influencing the reproductive tract (155). LS offers a good model 
with which to study the molecular background of these gynecological cancers for three 
important reasons: (1) the prevalence of these cancers is significantly increased in LS 
mutation carriers compared to the general population, thus providing reasonable numbers 
of tumors and other specimens for analysis (7, 8), (2) several lesions (benign and malignant) 
from the same patient are common (263), and (3) consecutive specimens are available from 
individuals taking part in a surveillance program to detect gynecological cancers which 
permits an investigation of the types of changes occurring before a carcinoma is detected.  
 
Beyond the known defects in MMR genes, LS-associated ovarian carcinomas have not been 
molecularly analyzed before. More is known about the endometrial carcinomas in women 
with LS, but there is very limited information about the molecular changes preceding 
endometrial cancer. Our findings revealed a novel and distinct genetic and epigenetic 
background of LS-associated ovarian and endometrial cancer as compared to sporadic 
corresponding cases, including MMR deficiency and TSG hypermethylation of specific 
genes appearing already in histologically normal endometrium, a high frequency of ARID1A 
expression alterations, and L1CAM overexpression, specifically in clear cell ovarian cancer. 
The novel findings of LS-associated ovarian and endometrial tumorigenesis are illustrated 
in Figures 14 and 15, respectively.
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1. 2 The role of deficient MMR 
Lynch mutation carriers have one defective allele in an MMR gene in every cell of their 
body. An acquired second hit in a particular MMR gene in a tissue of an LS mutation carrier 
compromises the MMR machinery and eventually leads to inactivation of MMR protein 
expression in the cell, conferring a growth advantage on the cell and the possibility to 
transform into a neoplastic cell. Thus, MMR deficiency in a pre-malignant specimen 
indicates an increased risk for tumor development. In fact, LS-associated ovarian and 
endometrial carcinomas displayed MMR deficiency already at histologically normal 
endometrium in 12% (12/99) of the cases compared to 0% (0/38) in sporadic cases 
(P=0.037), suggesting that this is a very early change in LS-associated tumorigenesis.  
 
Gynecological cancers could be almost completely prevented with prophylactic total 
hysterectomy and bilateral salpingo-oophorectomy (THBSO), and it has been shown to 
effectively decrease the risk of these cancers in LS women (264, 265). Women with LS are 
recommended to take part in regular endometrial surveillance against gynecological cancer 
every 2 to 3 years, starting at 30 to 40 years of age, but currently there are no further 
official guidelines to screen for gynecological cancer. Moreover, the optimal timing of 
prophylactic THBSO is debated (5, 266). It is intriguing to speculate whether analysis of 
MMR deficiency of endometrial specimens from LS patients taking part in gynecological 
screening might be beneficial in determining the timing of prophylactic THBSO and other 
treatment decisions (see below).  
 
The frequency of MMR deficiency in endometrial specimens increased with increasing 
histological abnormality of lesions in LS and sporadic series. The frequencies were 
exceptionally high in LS mutation carriers, 42% (5/12) in SH, 83% (5/6) in CH and 87% 
(33/38) in CAH. Moreover, an MMR deficiency was detected in all of the cases of CAH and 
appeared 1 to 9 years before the diagnosis of either ovarian or endometrial carcinoma (7/7 
= 100%). These patients with CAH did not have THBSO at the time of diagnosis either 
because the patient preferred not to undergo the surgery or CAH was not originally 
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diagnosed at the time of biopsy. Interestingly, also 67% (2/3) of the patients with SH and 
one case with a CH (1/1) diagnosis 1-2 years before carcinoma diagnosis, were shown to be 
MMR deficient. Similar to our findings, Faquin et al. (169) detected MMR deficiency by 
microsatellite analysis in one non-neoplastic endometrial specimen 7 years before the 
development of sporadic endometrioid endometrial carcinoma and argued that MSI 
diagnosis in endometrial tissues could predate the carcinoma diagnosis by years. 
Moreover, the diagnosis of aspiration biopsy specimens may be unreliable for pathologic 
inspection due to the fragmented nature of specimens, especially with postmenopausal 
women who often have an atrophic endometrium. Accordingly, pre-malignant (CAH) and 
even carcinoma cases may be diagnosed as benign (SH) and therefore, molecular analysis 
of hyperplasias could assist in treatment decisions, especially in borderline cases. 
 
1.3 ARID1A alterations and relationship with MMR 
Mutations of ARID1A are known to be common in sporadic clear cell (43-57%) and 
endometrioid (30%) ovarian carcinomas and endometrioid endometrial (40%) carcinoma 
(34, 39, 267), and many studies have shown a high correlation between ARID1A mutation 
by genetic analysis and deficient ARID1A expression by IHC (34, 267). In our study, the 
frequency of aberrant ARID1A expression was exceptionally high in LS-associated ovarian 
carcinomas (100%, 9/9 in clear cell and 86%, 12/14 in endometrioid ovarian carcinomas) 
compared to sporadic cases (0/39 in clear cell and 11%, 3/28 in endometrioid ovarian 
carcinomas) (P<0.001 in both histological types). Only 10% (1/10) of sporadic non-serous 
ovarian carcinomas with deficient MMR and showing MSI had lost their ARID1A expression. 
The loss of ARID1A expression was also high in endometrioid endometrial carcinoma, 
accounting for 61% (14/23) of the cases in comparison to 17% (6/35) in sporadic cases 
(P<0.001). In contrast to the low frequency of concurrent MSI and ARID1A aberrations in 
sporadic ovarian carcinomas (10%, 1/10), these alterations were frequent in endometrial 
carcinomas (67%, 4/6) (P=0.036). Bosse et al. (268) also detected a high frequency of 
aberrant ARID1A expression in sporadic MSI-high endometrial carcinomas (75%, 24/32), 
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but in contrast to our findings, they detected inactivation of ARID1A in only 14% (5/36) of 
their LS-associated cases. 
 
Mutations of ARID1A and consequent loss of protein expression have been detected in 
atypical endometriotic lesions adjacent to ovarian cancer, suggesting that this is an early 
event in ovarian tumorigenesis (267). No aberrant ARID1A expression was detected in 
progressive endometrial specimens (0/17, including NE, SH, CH, and CAH) from LS patients 
with ovarian carcinoma as the endpoint diagnosis, suggesting that ARID1A loss is a late 
event in LS-associated ovarian tumorigenesis or it possibly occurs only in atypical 
endometriosis preceding and/or adjacent to ovarian carcinoma which was not analyzed. 
On the other hand, a loss of ARID1A expression was detected in 15% (5/33) of complex 
hyperplasias (including one CH and 4 CAH) prior to or concurrent with LS-associated 
endometrial carcinoma. Similar findings were detected in sporadic cases of endometrial 
carcinoma by Werner et al. (269), who detected inactivation of ARID1A in complex atypical 
hyperplasia (16%) but no signs of this alteration in non-atypical hyperplasias. Our findings 
together with Werner et al. (269) propose that the loss of ARID1A expression is an early 
event in endometrial carcinoma regardless of origin (hereditary or sporadic) and could 
potentially be used as a biomarker in endometrial complex hyperplasia to evaluate the 
malignant potential of the lesion, and further to guide treatment decisions.  
 
Our findings raise a question about the relationship between MMR deficiency and the loss 
of ARID1A expression, since both were always present in clear cell carcinoma of the ovary 
and they are very common in endometrioid ovarian and endometrial carcinomas from LS 
mutation carriers and also frequent in sporadic MSI-high endometrial carcinomas. Bosse et 
al. (268) speculated that the loss of ARID1A expression was attributable to epigenetic 
inactivation of the MLH1 gene instead of being inactivated by mutations resulting from 
MSI. Our findings from consecutive specimens preceding cancer showed that MMR 
deficiency arises already in histologically normal endometrium and ARID1A later in complex 
hyperplasia. This discovery argues against the theory of Bosse et al. (268) and proposes 
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that ARID1A inactivation follows MSI and not vice versa. Arguments of MMR deficiency 
leading to aberrant ARID1A have also been hypothesized in gastric (270) and colorectal 
cancer (271, 272). In the study of Wang et al. (270), the somatic ARID1A mutation rate was 
found to be 12-61 fold higher compared to the general background mutation rate in MSI 
associated gastric carcinomas. Although mutations affecting ARID1A are typically nonsense 
and frameshift (34), Wang et al. (270) detected mainly insertions/deletions of short 
mononucleotide repeats in ARID1A in MMR-deficient cases suggesting that for some 
unknown reason, ARID1A is specifically targeted by MSI. A similar trend of high incidence 
of ARID1A insertions/deletions mutations associated with MMR deficiency in colorectal 
cancer was detected by Jones et al. (271) and Chou et al. (272) indicating that MMR-
deficiency often leads to aberrant ARID1A gene as the result of MSI. 
 
1.4 Epigenetic changes as early events 
Genetic modifications alone cannot explain the complex nature of LS-associated and 
sporadic ovarian and endometrial cancer. Epigenetics, including hypermethylation, is 
expected to play a major role in the LS-associated tumors, since deficient MMR machinery 
causes hypermutability and increases the possibility of alterations in other genes involved 
in cancer development (273). Some of the affected genes may be involved in epigenetic 
regulation which can cause hypermethylation of TSGs (274). Similar to MMR deficiency, 
hypermethylation of specific TSGs (frequently including RSK4, SPARC, HOXA10, HOXA9, 
RASSF1 and CDH13) was detected even in normal endometrium several years prior to the 
development of ovarian or endometrial carcinoma in LS cases, suggesting that these are 
early alterations in tumorigenesis. Our findings, together with published reports, support 
the concept that detection of specific epigenetic gene profiles in premalignant lesions and 
in cancer tissue may facilitate early detection, classification and treatment of ovarian and 
endometrial cancer (see also the next Chapter) (275, 276) .  
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2 Three-tiered categorization system proposed for endometrial specimens 
The main view at present is that type I endometrial carcinomas mainly originate from 
atypical hyperplasia (192). Therefore, the WHO2014 schema categorizes hyperplasias into 
two types, non-atypical (including SH and CH) or atypical (including SAH and CAH) (195). A 
correct classification of hyperplasia is highly important, since it guides treatment decisions. 
These decisions can be quite dramatic: Atypical hyperplasia is mainly treated with 
hysterectomy whereas medication is the standard treatment for hyperplasia without 
atypia (185).  
 
In contrast to the WHO2014 classification, our findings of MMR-deficiency, the loss of 
ARID1A expression, and the methylation status of TSG promoters divided progressive 
endometrial samples into three categories of combined histological types: NE plus SH 
(category I), CH plus CAH (category II), and endometrial carcinoma as its own entity 
(category III). Importantly, our results suggested that in addition to CAH, CH should be 
considered as a pre-neoplastic form of endometrial carcinoma. In particular, the average 
numbers of methylated TSGs in both panels (the panel of 24 general TSGs and the panel 
comprising of 7 endometrial and ovarian cancer related TSGs) and regardless of origin (LS 
or sporadic) were able to discriminate between categories I (NE + SH) and II (CH+CAH) and 
III (endometrial cancer). Our results are compatible with the idea of classes with low (I) and 
high (II, III) malignant potential. 
 
Similar to our observations, van der Putten et al. (190) found that the genetic profile for 
complex hyperplasias (both CH and CAH) differed from simple hyperplasias of both non-
atypical (SH) and atypical (SAH) type and stated that complex hyperplasia, regardless of 
atypia, seems to be the most important precursor for endometrial carcinoma. The 
categorizations of hyperplasia are still largely based on the original findings of Kurman et 
al. in 1985 (192), who reported that only 3% of complex hyperplasia without atypia (CH) 
progressed to cancer and partly because of this statement, CH has not been considered as 
a pre-neoplastic form of endometrial cancer. However, the study of Kurman et al. (192) 
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included only 29 cases of CH. A recent publication by Matsuo and colleagues (277) 
estimated a 21% risk of concurrent endometrial cancer with CH. In addition, one may also 
speculate whether the transition from CH to CAH is so fast that it is often not recognized, 
suggesting that CH should be regarded as pre-neoplastic lesion as well.  
 
Several biomarkers have been proposed to detect and predict the cancer risk in 
hyperplasias, but so far, these have not proven effective enough for application in a clinical 
setting (185). It is tempting to postulate that the methylation analysis of specific TSGs (and 
MMR status in cases of LS mutation carriers) could improve diagnostics and help to predict 
the malignant potential of hyperplastic lesion, either atypical or non-atypical. 
 
3 Is endometrial hyperplasia a component of ovarian tumorigenesis? 
Only a few studies have investigated the prevalence of endometrial hyperplasia occurring 
concurrently with ovarian cancer and the knowledge of this subject is poor (184, 278). 
Nonetheless, surprisingly high frequencies of atypical hyperplasia concurrent with ovarian 
carcinoma have been detected. Mingels et al. (184) reported that approximately half of the 
endometrioid and 29% of clear cell ovarian carcinomas present with concurrent atypical 
hyperplasia. These results were nearly identical to our findings of concurrent CAH with 
endometrioid (7/14, 50%) and clear cell ovarian cancer (2/9, 22%) from LS patients (Figure 
13). It is well known that endometrial hyperplasias are significant steps in endometrial 
tumorigenesis (185), but our findings together with those of Mingels et al. (184), raise the 
question of whether endometrial hyperplasias are also connected to ovarian 
tumorigenesis. Moreover, the correspondence of the molecular markers between complex 
hyperplasias and concurrent ovarian cancer (Figure 13) included in our studies, indicate 
that endometrial hyperplasias may have a role in the development of ovarian carcinoma. 
These findings should act as a springboard for additional research. In particular, the 
epigenetic findings may help to reveal relationships within samples reflecting the common 
origins (279). Indeed, hypermethylation of the same loci was often detected in hyperplasia 
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prior to or concurrent with ovarian cancer frequently in the HOXA10, HOXA9, RASSF1 and 
CDH13 genes.  
 
Mingels et al. (184) speculated that atypical hyperplasia could be caused by increased 
production of estrogen by the ovarian cancer, i.e. especially the endometrioid type ovarian 
cancer has been shown to increase estrogen levels. But since Mingels et al. (184) only 
investigated concurrently occurring samples, it is not known which abnormality occurred 
first, i.e. was it atypical hyperplasia or ovarian cancer? In our consecutive sample series, 
two LS patients, LOC1 and LOC22, were diagnosed with CAH but treated with hysterectomy 
only instead of THBSO. The patients ended up developing endometrioid and clear cell 
ovarian cancer three and seven years later, respectively.  Thus, our observations of CAH 
arising several years before the identification of ovarian carcinoma, are compatible with 
the possibility of CAH being an early step in ovarian tumorigenesis.  
 
Mingels et al. (184) hypothesized that concurrent atypical hyperplasia is a premalignant 
form of synchronous endometrial carcinoma. This is likely to be true, but additionally, our 
findings raise the question of whether a hyperplastic lesion in the endometrium could also 
metastasize to the ovary and thus be the precursor for ovarian cancer as well, since 
endometrial epithelial cells are the putative origins of endometrioid and clear cell ovarian 
tumors (280). Kelemen et al. (260) studied the risk factors of synchronous endometrial and 
ovarian tumors by multivariable models and observed that endometriosis in the ovary was 
associated with a decreased risk of synchronous tumors relative to clear cell and 
endometrioid ovarian-only tumors. Kelemen et al. (260) suggested that endometriosis is 
not a likely step in the development of synchronous endometrial and ovarian carcinomas, 
leaving room for the scenario that endometrial hyperplasia might represent this step in 
synchronous cases. 
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CONCLUDING REMARKS AND FUTURE PROSPECTS 
LS-associated ovarian cancer differs from its sporadic counterpart in several ways, but the 
molecular alterations behind these differences remain unanswered. This thesis work 
describes a novel genetic and epigenetic profile of LS-associated ovarian carcinomas: There 
was the virtually inevitable loss of ARID1A expression, a mismatch repair deficiency, a lack 
of KRAS and BRAF mutations, normal p53 expression, the unique hypermethylation profile 
of selected tumor suppressor genes and a lack of LINE-1 hypomethylation. Additionally, the 
frequency of PIK3CA mutations and L1CAM overexpression were common and comparable 
to that encountered in sporadic tumors of the same histological types. Moreover, we 
identified different hypermethylation profiles of selected genes in non-serous histological 
types of Lynch and sporadic ovarian carcinomas, as compared to sporadic serous ovarian 
tumors. The prominent differences discovered between ovarian tumors of Lynch and 
sporadic origin as well as between histological types help to explain the distinct behavior 
of these carcinomas and emphasize the need for individualized clinical management.  
 
Møller et al. (8) described the excellent survival in endometrial (98%) and ovarian (89%) 
cancer, but speculated that further investigation would be needed to determine the factors 
behind this favorable prognosis. Our results from genetic and epigenetic analysis indicate 
that LS-associated ovarian carcinomas have more favorable molecular characteristics 
compared to sporadic ovarian carcinomas. In addition to the novel molecular 
characteristics of LS-associated ovarian carcinomas, other possible explanations to account 
for the better prognosis need to be addressed; these will include surveillance and the 
consequent early detection of pre-neoplastic lesions of endometrial carcinoma and the 
subsequent detection of synchronous ovarian carcinoma, as well as clarifying the role of 
immunogenic factors and explaining the lack of metastatic features (like in colorectal 
cancer) (13, 183, 281).  
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Survival of ovarian cancer is poor, and regardless of major histological and molecular 
differences within different histological types of ovarian cancer, the therapy is similar in all 
patients. Indeed, the detection of driver mutations and epimutations between ovarian 
cancer subtypes may offer new opportunities in ovarian cancer management through 
subtype-specific care. At present, only two biomarkers, CA125 and HE4 (Human epididymis 
protein 4) for ovarian cancer monitoring have been approved by FDA (282-284), but more 
specific markers, especially biomarkers for early detection are urgently needed. In 
particular, epigenetic biomarkers involving DNA methylation would be ideal because of its 
reversible nature and the possibility of targeting a specific gene region (172). Our findings, 
together with other reports, suggest that alterations in DNA methylation profile are able 
to discriminate between non-serous and serous types of ovarian cancer. By selecting the 
most prominent markers, DNA methylation could be used as a biomarker to distinguish 
between different subtypes of ovarian cancer especially in borderline cases in which the 
diagnosis may be difficult by pathological inspection only.  
 
Molecular alterations that predict ovarian and endometrial cancer risk and progression 
identified in this thesis project may have valuable clinical significance. As discussed earlier, 
information obtained from hyperplastic lesions guides treatment decisions. Although the 
risk-reducing effect of gynecological surveillance or early detection of these has not been 
proven scientifically yet, for now women with LS are recommended to take part in 
endometrial biopsy screening every 2 to 3 years starting at 30-40 years of age (5, 266). 
Endometrial biopsies obtained from this kind of surveillance program could be most 
beneficial when analyzed with specific markers during the interval between the diagnosis 
of LS and possible prophylactic surgery.  Molecular changes detected in endometrial 
aspiration biopsies could identify those patients who would benefit from intensive 
screening and cancer prevention, including oral contraceptives, progestin therapy and 
aspirin-based chemoprevention that may be effective against LS-associated gynecological 
carcinomas (266, 285). Furthermore, molecular alterations could help to predict the 
optimal time point for prophylactic surgery. 
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Currently, nuclear atypia detected by histopathological inspection of endometrial 
hyperplasias, is the only characteristic that confers an elevated risk for endometrial 
carcinoma in the general population and an additional risk of ovarian cancer in Lynch 
mutation carriers. Important information of the histologically normal endometrial tissue of 
hyperplastic biopsy specimen may remain undetected if investigated by histopathological 
inspection alone. This warrants further investigation but already now the results strongly 
emphasize that molecular testing of specific markers from aspiration biopsies, such as 
detection of MMR-deficiency status or hypermethylation profiles of specific gene 
promoters can provide more information of the malignant potential of pre-neoplastic 
specimens and clinical behaviour of tumor specimens. The results would allow more 
efficient counselling, help to select cases more suitable for non-surgical treatment of 
endometrial hyperplasia, guide treatment options in hereditary and sporadic cases and 
facilitate in the selection of the optimal timing of THBSO in women with Lynch syndrome. 
Indeed, our findings from the consecutive sample series prior to the appearance of ovarian 
and endometrial cancer, suggest that the precursor for endometrial cancer (or possibly 
even ovarian cancer) can be detected from aspiration biopsies taken from histologically 
normal endometrium several years before any carcinoma diagnosis.  
 
Our findings, together with findings from others, suggest that complex hyperplasia with 
and without atypia of LS and sporadic origin should be considered as equally important 
precursors for endometrial carcinoma progression and these findings should be included 
in considerations of treatment decisions. In addition, in the future, it could be investigated 
whether the histological classification should be combined with information from 
molecular markers (such as MSI status, ARID1A expression, KRAS) in order to predict the 
risk for endometrial carcinoma progression. 
 
Our molecular analyses emphasize the shared background of LS-associated synchronous 
endometrial and ovarian carcinomas and the possibility of metastatic disease. Moreover, 
molecular analysis of endometrial hyperplasias collected as a part of long-term surveillance 
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program before or concomitant with endometrial and/or ovarian cancer revealed 
concordance in alterations (MMR-status and hypermethylation profile of selected TSGs 
appearing already in histologically normal endometrium and the loss of ARID1A expression 
being evident in endometrial hyperplasias), pointing to an early convergence of 
endometrial and ovarian tumor development. If one wishes to obtain a broader 
perspective, it would be important to supplement our findings from LS specimens with 
results from synchronous sporadic gynecological carcinomas. 
 
Interestingly, the examination of consecutive specimens revealed that endometrial 
hyperplasias prior to or concurrent with ovarian carcinoma exhibit similar degrees of 
molecular alterations as compared to endometrial carcinoma. This discovery reveals that 
in addition to endometrial tumorigenesis, endometrial hyperplasia may also be connected 
to ovarian carcinogenesis. Overall, our observations of multilevel ties between endometrial 
and ovarian tumor development suggest that always when a pre-malignant or malignant 
endometrial lesion is detected, the possibility of ovarian cancer should be kept in mind and 
vice versa. 
 
In the future, it would be interesting to design a more comprehensive MS-MLPA based 
assay to detect methylation of the most prominent epigenetic biomarkers (including RSK4, 
SPARC, PROM1, HOXA10, HOXA9, WT1-AS, SFRP2, OPCML, MIR34B, APC, RASSF1, TP73 and 
CDH13) in a single assay and to investigate the markers in larger sample cohorts. A digital 
MLPA assay (286) has been recently developed to detect copy number alterations in up to 
a thousand target sequences, and a similar digital solution could be designed for MS-MLPA. 
This digital MS-MLPA test would be perfect for our purposes. In fact, if we were able to 
identify reliable and common epigenetic alterations preceding endometrial and ovarian 
cancer, these alterations could be used as epigenetic biomarkers which would not only 
further assist in the early detection but also help to predict prognosis and monitor the 
treatment response.  
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Genetic and epigenetic analysis of LS-associated ovarian and endometrial carcinomas on a 
genome-wide scale will be an obvious next step. Our truly interesting findings of the 
possible endometrial hyperplasia step involved in the development of ovarian carcinoma 
in women with LS is a springboard for additional research. For now, it remains to be 
resolved whether endometrial hyperplasia serves as a precursor lesion for endometrial 
carcinoma alone or could it also be relevant for ovarian tumorigenesis. Therefore, it would 
be especially important to find a suitable method to examine the whole methylome and 
genome of consecutive endometrial samples prior to endometrial and ovarian carcinoma. 
This genome-wide analysis could help to reveal the epigenetic relationships between 
specimens as well as identifying more specific and early genetic changes contributing to 
these carcinomas, and hopefully resolving whether endometrial hyperplasia is a precursor 
of ovarian tumorigenesis. At present, the problem is that most genome-wide methods 
require high quality and/or large quantities of DNA to produce reliable data and are 
therefore not suitable for FFPE samples. In particular, the amount and quality of DNA 
extracted from endometrial aspiration biopsies are mainly poor and inadequate and cannot 
be used to perform these whole genome analyses. Fortunately, methods are developing at 
a high speed and hopefully soon there will be an assay available to fulfill our needs. 
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